

Review Article

Natural products and phytochemical nanoformulations targeting mitochondria in oncotherapy: an updated review on resveratrol

Milad Ashrafizadeh¹, Sara Javanmardi², Masoumeh Moradi-Ozarlou³, Reza Mohammadinejad⁴, Tahereh Farkhondeh⁵, Saeed Samarghandian^{6,7} and  Manoj Garg⁸

¹Department of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran; ²Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran; ³Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran; ⁴Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran; ⁵Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran; ⁶Healthy Ageing Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran; ⁷Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran; ⁸Amity Institute of Molecular Medicine and Stem cell Research (AIMMSCR), Amity University, Noida, Uttar Pradesh 201313, India

Correspondence: Saeed Samarghandian (samarghandians1@nums.ac.ir) or Manoj Garg (mgarg@amity.edu, nuscsimg@gmail.com)



Mitochondria are intracellular organelles with two distinct membranes, known as an outer mitochondrial membrane and inner cell membrane. Originally, mitochondria have been derived from bacteria. The main function of mitochondria is the production of ATP. However, this important organelle indirectly protects cells by consuming oxygen in the route of energy generation. It has been found that mitochondria are actively involved in the induction of the intrinsic pathways of apoptosis. So, there have been efforts to sustain mitochondrial homeostasis and inhibit its dysfunction. Notably, due to the potential role of mitochondria in the stimulation of apoptosis, this organelle is a promising target in cancer therapy. Resveratrol is a non-flavonoid polyphenol that exhibits significant pharmacological effects such as antioxidant, anti-diabetic, anti-inflammatory and anti-tumor. The anti-tumor activity of resveratrol may be a consequence of its effect on mitochondria. Multiple studies have investigated the relationship between resveratrol and mitochondria, and it has been demonstrated that resveratrol is able to significantly enhance the concentration of reactive oxygen species, leading to the mitochondrial dysfunction and consequently, apoptosis induction. A number of signaling pathways such as sirtuin and NF- κ B may contribute to the mitochondrial-mediated apoptosis by resveratrol. Besides, resveratrol shifts cellular metabolism from glycolysis into mitochondrial respiration to induce cellular death in cancer cells. In the present review, we discuss the possible interactions between resveratrol and mitochondria, and its potential application in cancer therapy.

Introduction

Naturally occurring compounds are beneficial in the treatment of pathological events due to their excellent therapeutic and biological activities [1,2]. It is suggested that plant-derived chemicals are less harmful with minimal toxicity [3,4]. Resveratrol is a naturally occurring polyphenol exclusively found in a number of fruits and vegetables such as blueberries, grape, and peanut [5]. This important compound has a variety of pharmacological and health-promoting impacts such as antioxidant [6], anti-inflammatory [7], anti-tumor [8], anti-diabetic [9], hepatoprotective [10], neuroprotective [11] and cardioprotective [12], and is capable of improving dyslipidemia [13]. These therapeutic impacts of resveratrol have led to its extensive application in the treatment of various disorders. Accumulating data demonstrates that resveratrol is able to target multiple molecular signaling pathways to exert its therapeutic impacts. For

Received: 04 February 2020
Revised: 11 March 2020
Accepted: 12 March 2020

Accepted Manuscript online:
12 March 2020
Version of Record published:
03 April 2020

instance, in term of anti-tumor activity, resveratrol is capable of inhibiting the molecular pathways involved in the invasion and malignancy of cancer cells. Administration of resveratrol is associated with the down-regulation of the CXCR4 signaling pathway, leading to the inhibition of epithelial-to-mesenchymal transition (EMT) [14]. Resveratrol is advantageous in improving the potential of chemotherapy. Paclitaxel (PTX) is one of the most common chemotherapeutic agents in cancer therapy. However, the resistance of cancer cells is related to its reduced anti-tumor activity. Treatment of cancer cells with resveratrol sensitizes cancer cells to PTX therapy [15]. Besides, resveratrol up-regulates the expression of DUSP1 to enhance the efficacy of cisplatin in chemotherapy and eradication of prostate cancer cells [16]. Resveratrol can be considered as a promising candidate in the treatment of neurological disorders (NDs). A newly published article has questioned the role of resveratrol in the alleviation of cognitive deficits. Aggregations of amyloid-beta ($A\beta$) plaques and microtubule-associated protein tau significantly enhance the chance of Alzheimer's disease (AD) development. There have been attempts to reduce or inhibit this aggregation. By suppressing the accumulation of protein tau, Res remarkably diminishes the cytotoxicity and inhibits neuroinflammation, leading to the amelioration of memory deficits [17–19].

Diabetes mellitus (DM) is a chronic metabolic disorder associated with an increase in the levels of serum glucose [20]. This disorder negatively affects various parts of the body demanding immediate management and treatment [21]. Resveratrol has demonstrated great potential in the treatment of DM. Insulin resistance is one of the most challenging difficulties related to DM. Down-regulation of SNARE protein remarkably enhances insulin resistance [22]. Resveratrol-loaded solid lipid nanoparticles (Res-SLNs) are able to reduce insulin resistance. Administration of Res-SLNs significantly decreased oxidative stress and inhibited weight loss. Investigation of molecular signaling pathways demonstrated that Res-SLNs are capable of the up-regulation of SNARE resulting in attenuation of DM [23]. DM harmfully affects reproductive function. Based on the therapeutic effects of resveratrol, its administration can be advantageous in DM treatment. Resveratrol remarkably increases the motility and viability of sperm and promotes DNA integrity during DM [24]. These studies support the protective effects of resveratrol against human diseases.

Resveratrol

In spite of having great pharmacological effects, there are a number of factors that limit the therapeutic impacts of resveratrol. This compound has poor bioavailability after oral administration [25,26], restricting its activities. Rapid metabolism and low solubility are two factors responsible for the poor bioavailability of resveratrol [27,28]. For *in vivo* experiments, resveratrol is dissolved in 10% ethanol [29,30] and for *in vitro* purposes, resveratrol is dissolved in 0.2% DMSO [31,32]. Due to the unexpected harmful effects of resveratrol in 0.2% DMSO on cells and tissues, resveratrol and DMSO combination is of interest in experiments related to the cultured cells (*in vitro*) [33,34]. So, it is obvious that poor bioavailability of resveratrol not only has limited its therapeutic and biological impacts, but also has led to some effects on the administration route of resveratrol. A variety of attempts have been performed to improve the bioavailability of resveratrol and among them, the nano-based drug delivery systems are of importance [35]. In a newly published article, Thiye and colleagues synthesized resveratrol-loaded gold nanoparticles to enhance the anti-tumor potential of resveratrol against breast, pancreatic and prostate cancers. The findings demonstrated that the enhanced corona of resveratrol on gold nanoparticles significantly promotes the bioavailability of resveratrol, leading to the reduced viability and proliferation of cancer cells [36]. Besides, resveratrol-loaded lipid-core nanocapsules have higher antioxidant and anti-inflammatory activities compared to the resveratrol alone [37]. Overall, polymeric nanoparticles [38,39], solid lipid nanoparticles [40,41], self-emulsifying drug delivery systems [42,43], nanoemulsions [44,45], liposomes [46,47], nanosuspensions [48] and nanofibers [49] have been developed for delivery of resveratrol and the results have been satisfactory.

Resveratrol in the treatment of cancer

Resveratrol has demonstrated great potential in the treatment of various cancers due to its capability in targeting various molecular pathways [50–54]. By inhibition of TNF-receptor associated factor 6 (TRAF6), resveratrol inhibits EMT to reduce the invasion of prostate cancer cells [55]. In colon cancer cells, resveratrol-loaded solid lipid nanoparticles remarkably stimulate apoptotic cell death to diminish the growth and proliferation of cancer cells [56]. In addition to apoptosis, resveratrol induces cell cycle arrest in cancer cells [57,58]. Due to its demethylation capability, resveratrol enhances the sensitivity of anaplastic thyroid cancer cells to retinoic acid [59]. Notably, resveratrol can be applied in cancer immunotherapy. Programmed death-1 (PD-1) is associated with reduced severity of the immune system during cancer progression. By administration of resveratrol, PD-1 is accumulated in endoplasmic reticulum and its stabilization is inhibited, leading to the increased anti-tumor activity of T-cells [60].

Resveratrol administration is advantageous in the treatment of colon cancer by triggering signaling pathways that can lead to the stimulation of apoptosis. A combination of resveratrol and As₂O₃ diminishes the expression of hERG channels on the cell membrane. This results in the dissociation of hERG and integrin β 1 to induce apoptosis in colon cancer cells [61]. Furthermore, resveratrol has shown great potential in the treatment of oral cancer. Thyroxine is associated with enhanced proliferation and progression of oral cancer cells by down-regulation of apoptotic factor BAD and up-regulation of PD-1. Resveratrol exerts an inhibitory effect on the function of thyroxine so that resveratrol supplementation enhances the expression of BAD and inhibits PD-1 to suppress oral cancer cells [62]. By down-regulation of the snail signaling pathway, resveratrol reduces EMT to inhibit the invasion of colon cancer cells [63]. It is worth mentioning that resveratrol activates tumor suppressor Rad9 to induce premature senescence in lung and breast cancer cells [64]. Another published article also demonstrates the capability of resveratrol in the regulation of epigenetic factors [65]. These studies reveal the potential activity of resveratrol as an anti-tumor agent.

Overall, triggering reactive oxygen species (ROS) production is a promising strategy in cancer therapy, since these reactive species are involved in stimulation of apoptosis through mitochondrial dysfunction and much attention has been directed toward enhancing the ROS generation in cancer cells to suppress their malignancy and proliferation [66,67]. To date, there has been no article to investigate the relationship between the inhibitory effect of resveratrol on ROS production and its anti-tumor activity. However, the accumulating data have shown that the major mechanism for the antioxidant activity of resveratrol is related to its effect on the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway. Resveratrol, by activation of the Nrf2 signaling pathway, ameliorates oxidative stress [68] to improve colitis [69], arthritis [63], diabetes [70] and non-alcoholic fatty liver disease [71].

Mitochondria at a glance

Mitochondria are one of the most important intracellular organelles with the size as low as one micron [72,73]. They are available in two characteristic forms including granular form and filamentary form. Originally, mitochondria have been derived from aerobic α -proteobacteria. As a consequence, it has been demonstrated that a variety of mitochondrial proteins have bacterial origin [74]. The number of mitochondria varies in each cell and exists in all eukaryotic cells except mature erythrocytes. Due to the bacterial origin of mitochondria, this important organelle has two distinct membranes known as the outer mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM). Notably, each of these membranes has its own functions. The IMM shrivels inwards resulting in the formation of folds known as cristae that surround the matrix. However, OMM has a more vital function. OMM is responsible for the exchange of metabolites by its pores through passive diffusion and translocases located on the OMM. Besides, OMM protects the cytosol against damages such as degradation by inhibition of releasing ROS and mitochondrial DNA (mtDNA). Mitochondria are well-known as the powerhouse of the cell and contribute to the production of adenosine triphosphate (ATP). The mitochondria generate energy in the form of ATP via oxidative phosphorylation pathway. Regardless of the essential function of mitochondria in providing energy, this intracellular organelle significantly diminishes the levels of oxygen in the cell by consuming it in energy production, leading to a substantial decrease in the concentration of this potentially toxic substance.

Mitochondria and apoptosis

Although much emphasis has been directed towards the role of mitochondria in providing energy, mitochondria play a significant role in maintaining homeostasis [75,76]. The structure of mitochondria is of importance in induction or inhibition of apoptotic cell death [77,78]. Accumulating data demonstrates that mitochondria are the central gateway of the intrinsic pathway of apoptosis [79,80]. This reveals the potential role of mitochondria in the regulation of life and death [81,82]. The beginning point in the stimulation of apoptotic cell death by mitochondria is the release of cytochrome C (Cyt C) into the cytosol. This occurs after the mitochondrial outer membrane permeabilization (MOMP) [83,84]. The lethal functions are controlled by MOMP during apoptotic cell death that is mediated via the proteins involved in the formation of pores including pro-apoptotic proteins include B-cell lymphoma 2 (Bcl-2), Bcl-2 associated x protein (Bax) and Bcl-2 antagonist/killer protein (Bak) [85]. Increasing evidence shows that mitochondria contribute to necrotic cell death and are able to disrupt Ca²⁺ homeostasis and ROS production [86,87]. In addition to the Cyt C, other molecules such as Samc/Diablo and endonuclease G are released into the cytosol. The release of cyt C into cytosol occurs in response to the stress conditions such as high ROS concentration and DNA damage [88]. Next, cyt C leads to the formation of apoptosome containing procaspase-9 and apoptotic protease activating factor 1 (Apaf-1). Consequently, caspase-9 stimulates caspase cascade, resulting in apoptosis. Caspase-3 is one of the targets of caspase-9. After the generation of caspase-3 from pro-caspase-3 by the stimulation of caspase-9, the caspase-3 induces morphological alterations of apoptosis in cells such as chromatin condensation, DNA fragmentation and blebbing to

direct the cell toward apoptotic cell death [89]. Noteworthy, caspase-9 also activates caspase-7 and an increase occurs in both caspase-7 and -3. Caspase-7 along with caspase-3 mediates the induction of apoptosis in target cells [90]. The cells undergoing apoptosis have a number of morphological signs such as membrane blebbing, cell shrinking, chromatin condensation and apoptotic bodies [91,92].

Mitochondria and cancer

Obviously, mitochondrial dysfunction is associated with a variety of pathological conditions such as NDs [93], hepatic disorders [69] and so on. This is due to the potential role of mitochondria in the induction of apoptotic cell death. However, this intracellular organelle can be targeted as a therapeutic candidate in cancer therapy. Although much attention has been made in the regulation of mitochondrial-mediated apoptosis and preserving mitochondrial homeostasis to prevent the development of pathological conditions, it seems that the administration of agents targeting mitochondria is of importance in cancer therapy. Orientin is a naturally occurring flavonoid with great pharmacological impacts, particularly anti-tumor activity [94,95]. It is held that the administration of orientin is of interest in the treatment of colorectal cancer. Orientin induces apoptotic cell death in colorectal cancer cells. By activation of pro-apoptotic proteins, orientin disrupts the integrity of OMM to release cyt C and Smac/Diablo into cytosol resulting in stimulation of mitochondrial-mediated apoptosis [96]. Accumulating data demonstrates that breast cancer is one of the most common malignancies in women worldwide [97]. It has been demonstrated that the conventional therapeutic strategies such as chemotherapy and radiotherapy are no longer efficient due to the resistance of breast cancer cells [98,99]. Administration of plant-derived chemicals can sensitize cancer cells into radiotherapy and chemotherapy. Berberine is a potent anti-tumor agent and 13-ethylberberine (13-EBR) is one of its derivatives [100,101]. Enhancing the production of ROS is beneficial in cancer therapy by induction of the extrinsic and intrinsic pathways of apoptosis [102,103]. 13-EBR uses the same strategy for breast cancer therapy. Treating MDA-MB-231 breast cancer cells with 13-EBR is associated with the elevated concentration of ROS. As a consequence, an increase occurs in the level of pro-apoptotic factor BAX, while anti-apoptotic factor Bcl-2 undergoes down-regulation. Besides, 13-EBR enhances the levels of caspase-3, caspase-9 and poly (ADP-ribose) polymerase (PARP) showing the mitochondrial-induced apoptosis [104]. Lycorine is another plant-derived chemical belonging to the *Amaryllidaceae* plant family [105–107]. Administration of lycorine substantially reduces mitochondrial membrane potential (MMP) that is accompanied by the release of Cyt C into cytosol leading to apoptosis induction [96]. On the other hand, Rho-associated protein kinase (ROCK) contributes to the regulation of important biological processes such as cell proliferation, cell differentiation and cell apoptosis [108,109]. ROCK1 is involved in cancer progression and its inhibition occurs during cancer metastasis [110,111]. Lycorine stimulates mitochondrial-mediated apoptosis by up-regulation of ROCK1 [112]. Taking everything into account, it seems that naturally occurring compounds are able to target mitochondrial function in the induction of apoptosis in cancer cells [113,114].

Mitochondria play a significant role in energy production and regulation of cell death. Any impairment in the homeostasis of mitochondria can adversely affect the OMM resulting in releasing cyt C and induction of apoptotic cell death. Notably, the inhibition of mitochondrial dysfunction is of interest in the treatment of pathological conditions such as NDs and renal fibrosis to prevent further damage to these organs. However, the story is completely different in cancer cells. In cancer therapy, agents targeting mitochondria are applied to impair the homeostasis of this intracellular organelle leading to the stimulation of apoptotic cell death and decreased viability and proliferation of cancer cells.

Regulation of mitochondria by plant-derived chemicals

Nowadays, the application of naturally occurring compounds has undergone an increase for management of various chronic diseases [115,116]. This is due to the great pharmacological impacts of plant-derived chemicals that have made them appropriate options in the treatment of a variety of disorders such as cancer, diabetes [117], cardiovascular diseases [118], autoimmune diseases [119] and infectious diseases [120]. There have been efforts to reveal the underlying mechanism of action of these agents [3,121]. It has been demonstrated that plant-derived chemicals are capable of affecting molecular signaling pathways and organelles in the treatment of diseases [3,4,115,121]. For instance, resveratrol can affect the ER to exert its therapeutic impacts [116]. This story is also similar for curcumin [62], berberine [80], emodin [122] and other natural products. So, it is conspicuous that organelles can be considered as potential targets of these natural products.

In the current section, we discuss the impact of naturally occurring compounds on mitochondria to direct the next sections about the special relationship of resveratrol and mitochondria in cancer therapy. Curcumin is one of the

most important components of *Curcuma longa* with excellent therapeutic impacts including anti-tumor [123], hepatoprotective [124], cardioprotective [125], anti-diabetic [126], antioxidant [127] and anti-inflammatory [128]. Newly published articles have shed some light on the ability of curcumin in targeting mitochondria. Curcumin administration is considered as a promising strategy in cancer therapy by targeting mitochondria, impairing MMP, induction of the intrinsic pathway of apoptosis and consequently, reducing the viability and proliferation of cancer cells [129]. The plant-derived chemicals are well-known due to their great antioxidant impacts. It has been shown that high doses of natural antioxidants function as inducers of oxidative stress. In acute lymphoblastic leukemia, the administration of curcumin enhances the generation of ROS, leading to the activation of the intrinsic pathway of apoptosis via induction of mitochondrial dysfunction [130]. In addition to cancer therapy, the administration of curcumin is beneficial in the treatment of NDs by targeting mitochondria [131].

Emodin is an anthraquinone derivative with pharmacological effects such as antioxidant, anti-inflammatory, anti-tumor and neuroprotective [127]. Emodin supplementation is suggested to be beneficial in the treatment of colon cancer by regulation of molecular signaling pathways such as MAPK/JNK, PI3K/Akt, NF- κ B and STAT to impair MMP, leading to the reduced viability and growth of tumor cells through mitochondrial-dependent manner [132]. Besides, accumulating evidence demonstrates that the side effects of emodin may be a result of emodin impact on mitochondria. The administration of emodin is associated with apoptotic cell death in hepatocytes by enhancing ROS levels and impairing MMP [133].

Berberine is another naturally occurring compound with great therapeutic and biological activities in clinical trials, *in vivo* and *in vitro* experiments [134,135]. The effects of berberine on mitochondria are associated with anti-tumor and protective activities of berberine. Co-delivery of berberine and paclitaxel is advantageous in cancer therapy, and promotes the efficacy of chemotherapy, since berberine selectively targets mitochondria, enhances the concentration of ROS, resulting in stimulation of apoptotic cell death [136]. Furthermore, berberine supplementation is a promising strategy in the amelioration of neurotoxicity from amyloid beta-mediated mitochondrial dysfunction [137] and oxidative stress-induced mitochondrial impairment [138]. These studies highlight the fact that mitochondrial dysfunction is beneficial in cancer therapy and using naturally occurring antioxidants such as curcumin, emodin, berberine and particularly, resveratrol can reduce the viability and growth of tumor cells by stimulation of mitochondrial dysfunction.

Resveratrol affects mitochondria in cancer therapy

Resveratrol and oxidative stress

Notably, plant-derived chemicals are usually applied for their high antioxidant activity. This is due to the potential role of ROS in the development of cancer [139,140]. However, the application of the high amount of these antioxidant agents is associated with their conversion to pro-oxidants resulting in the production of high levels of ROS [141,142]. This feature is used in cancer therapy. On the other hand, the enhanced concentration of ROS and consequently, the stimulation of oxidative stress displays tumor suppressor and oncogene activity [143]. A variety of molecular pathways contribute to the association of oxidative stress with cancer development or cancer suppression. It has been demonstrated that the interaction of ROS and non-coding RNAs is involved in cancer progression and inhibition. This dual role of oxidative stress and its function as a double-edged sword should be considered in treatment of cancer. Resveratrol uses same strategy in combating HepG2 cells. Administration of resveratrol enhances the concentration of ROS in cytosol of cancer cells. By upregulation of Bax and down-regulation of Bcl-2, the integrity of OMM is disrupted. Then, cyt C releases into the cytosol to form Apaf1-procaspase-9 complex resulting in apoptotic cell death [144]. In fact, resveratrol stimulates apoptotic cell death through improving the oxidative phosphorylation [145]. The studies approve that the high concentration of resveratrol or long-term exposure to resveratrol is related to a perturbation in the oxidative-antioxidative balance leading to apoptotic cell death [146–150].

Resveratrol and apoptosis

Apoptosis is still a common way in reducing the viability and proliferation of cancer cells. However, there are concerns about this kind of cell death. Although apoptosis is beneficial in cancer therapy, there are controversial discussions showing that induction of apoptosis may be related to the enhanced proliferation of other surviving cancer cells. This phenomenon is known as apoptosis-induced proliferation (AIP) [151,152]. So, before making any decision in treatment of cancer, all the consequences should be considered to have an efficient chemotherapy. As it was mentioned, resveratrol uses various strategies to stimulate apoptosis in cancer therapy. One of them is making an increase in the level of oxidative stress that in turn, releases cyt C into cytosol resulting in apoptosis. However, resveratrol is capable of stimulation of mitochondrial dysfunction. Cisplatin is one of the chemotherapeutic agents that is extensively applied

in the field of cancer therapy. Resveratrol is able to sensitize tumor cells to cisplatin therapy. Administration of resveratrol triggers mitochondrial dysfunction by mitochondrial membrane potential loss resulting in the induction of apoptosis in tumor cells [45]. Besides, resveratrol administration is associated with reduced viability and malignancy of prostate cancer cells by disruption of mitochondrial DNA [153]. Overall, cancer cells prefer to use glycolysis for the generation of ATP and simultaneously, enhance their glucose uptake known as Warburg effect [154]. Accumulating data demonstrates that the anti-tumor activity of resveratrol is a consequence of reducing the glucose metabolism of cancer cells [155–157]. In colon cancer cells, administration of resveratrol alters the metabolism into fatty acid oxidation to stimulate oxidative stress. This study highlights the potential role of mitochondrial respiration induction by resveratrol in cancer therapy [158]. However, the anti-tumor activity of resveratrol against various cancer cells is different. Resveratrol demonstrates highest anti-tumor activity against leukemia cells mediated through mitochondrial dysfunction. This high anti-tumor activity is a result of mitochondrial-mediated apoptosis. Investigation of molecular pathways revealed that the administration of resveratrol down-regulates Akt resulting in decreased invasion and malignancy of leukemia cells [159]. These studies demonstrate that resveratrol is capable of the induction of apoptotic cell death in cancer cells via mitochondrial-mediated apoptosis [160–167].

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the potential candidates in the stimulation of apoptotic cell death in tumor cells. The apoptosis is induced via attachment of death-inducing signaling complex into death receptors DR4 and DR5. Next, this complex binds to the Fas-associated protein with death domain and caspase-8 to activate caspase-9 and consequently, caspase-3 resulting in stimulation of apoptosis [168,169]. There is a close connection between TRAIL-mediated apoptosis and mitochondria. It seems that cyt C and Smac/Diablo released from mitochondria regulate TRAIL-mediated apoptosis [170]. One of the beneficial impacts of TRAIL is that this pathway induces apoptosis in tumor cells without harmfully affecting normal cells. However, some of the cancer cells acquire resistance into TRAIL-mediated apoptosis that in turn, significantly reduces the efficacy of agents activating the TRAIL pathway in cancer therapy. Hence, there have been efforts to sensitize cancer cells into TRAIL-mediated apoptosis. Resveratrol has demonstrated great potential in this case. Administration of resveratrol is accompanied by a loss of OMM and an elevation in ROS production that releases cyt C into the cytosol. This mitochondrial dysfunction is associated with a decrease in Bcl-2 and Bcl-xl in NSCLC cells leading to the sensitization of cancer cells into TRAIL-mediated apoptosis. Investigation of molecular signaling pathways demonstrated that resveratrol reduces the expression of the Akt/NF- κ B signaling pathway to sensitize cancer cells into TRAIL-mediated apoptosis [171].

Resveratrol and mitochondrial fusion and fission

Although much emphasis was put on either enhancing the ROS generation or induction of mitochondrial dysfunction, targeting other dynamic aspects of mitochondria is also beneficial in cancer therapy. Mitochondria play a significant role in cell growth and cell division. The fusion and fragmentation of mitochondria occur in G1/S and G2/M, respectively. Notably, cell growth can be negatively affected by the induction of fusion or inhibition of fission since mitochondrial fragmentation is vital for cell growth [172–175]. Mitofusin-2 (Mfn2) is one of the most important proteins that accelerates mitochondrial fusion [176]. Resveratrol up-regulates the expression of Mfn2 to stimulate mitochondrial fusion, leading to the decreased viability and proliferation of cancer cells [177]. Triggering mitochondrial fission is another promising strategy in cancer therapy. Similar to mitochondrial fusion, induction of fission is associated with an impairment in cell division and cell growth. Resveratrol administration significantly enhances the expression of microRNA (miR)-326 to down-regulate PKM2 resulting in mitochondrial fission that in turn, decreases the viability and proliferation of tumor cells [178].

Resveratrol and Ca²⁺ signaling

There is a close connection between the ER and mitochondria. Due to the high loading of proteins into the ER for correct folding, this organelle needs a high amount of ATP produced by mitochondria [179,180]. As a consequence, the transportation of Ca²⁺ occurs from ER into mitochondria to promote the ATP generation [181]. Next, produced ATP can translocate into the ER to provide its energy demand [182]. It seems that the transportation of Ca²⁺ is a vital step in the ER and mitochondrial connection [183]. Accumulating data demonstrates that mitochondria are capable of regulating the Ca²⁺ concentration and high levels of Ca²⁺ negatively affect the potential of OMM [184–186]. A combination of resveratrol and piceatannol remarkably enhances the uptake of Ca²⁺ by mitochondria. Decreased expression of sarco/endoplasmic reticulum Ca²⁺ ATPase (SERCA) facilitates the Ca²⁺ uptake by mitochondria of cancer cells, leading to the stimulation of cell death [187].

Resveratrol and sirtuin signaling pathway

Sirtuins are NAD⁺-dependent proteins that play a significant role in the regulation of biological processes in cancer cells such as metabolism and genome structure [188]. Sirtuin 1 (Sirt1) is one of the key members of the sirtuin family and its induction is associated with diminished viability and proliferation of tumor cells [189,190]. There is a bidirectional interaction between Sirt1 and AMP-activated protein kinase (AMPK) pathway. The forkhead box O3 (FoxO3) and LKB1 are involved in the SIRT1/AMPK axis. It has been reported that the SIRT1/AMPK axis is of importance in mitochondrial biogenesis, fission, fusion, and mitophagy [191]. Administration of resveratrol considerably reduces the viability and mitochondrial respiration of breast cancer cells, while it stimulates cell cycle arrest. It was found that resveratrol exerts these anti-tumor impacts by affecting mitochondrial respiration through Sirt1 up-regulation [192].

Resveratrol and autophagy

Autophagy is a catabolic process that provides energy during starvation by the degradation of aged or damaged organelles and components [193]. Autophagy inhibition is widely observed in NDs such as AD [194]. However, autophagy plays a dual role in cancer cells. The increasing evidence demonstrates both the inhibitory and stimulatory impact of autophagy activation on the progression and viability of cancer cells [195,196]. Based on the most recent studies, autophagy stimulation is suggested to be advantageous in cancer therapy and enhancing the potential of chemotherapy [197]. However, other recent studies shed some light on the fact that autophagy is a protective mechanism and elevates the viability and proliferation of cancer cells [198,199]. Also, another study shows that the stimulation of autophagy is related to the reduced viability of tumor cells [200]. Furthermore, there is a close relationship between autophagy and apoptosis. The cells induce autophagy to ameliorate stress and look at autophagy as a protective and pro-survival mechanism. When the autophagy process is no longer able to maintain the survival of cells, the cells undergoing stress stimulate apoptosis through different pathways, for instance through ER stress. Resveratrol leads to the mitochondrial dysfunction by making damage to mtDNA that in turn, stimulates autophagy. Inhibition of autophagy enhances the mitochondrial-mediated apoptosis by resveratrol in colon cancer cells [201], showing the pro-survival role of autophagy. Signal transducers and activator of transcription 3 (STAT3) is a signaling pathway involved in the progression and malignancy of cancer cells [202]. Resveratrol has demonstrated great potential in the regulation of the STAT3 signaling pathway [203,204]. Resveratrol treatment enhances the level of cyt C in the cytosol to induce apoptotic and autophagic cell death. These anti-tumor effects are mediated by mitochondrial dysfunction through STAT3 inhibition [205].

Resveratrol and NAF-1 protein

The nutrient-deprivation autophagy factor 1 (NAF-1) protein is a vital protein located on the OMM and ER [206]. NAF-1 plays a significant role in maintaining the integrity and function of mitochondria [207]. Besides, NAF-1 is associated with longevity since its expression undergoes down-regulation in elder mice than younger mice [208]. NAF-1 deficiency triggers mitochondrial impairment leading to autophagy induction for removal of damaged organelles [206]. Accumulating data demonstrates that NAF-1 functions as a prognostic signature and its up-regulation occurs in cancer cells [209,210]. Resveratrol targets NAF-1 protein in the treatment of pancreatic cancer cells. Resveratrol enhances ROS generation to activate the Nrf2 signaling pathway, leading to a diminution in the expression of NAF-1. The down-regulated NAF-1 stimulates apoptotic cell death, resulting in decreased viability and proliferation of pancreatic cancer cells [211].

Resveratrol, glycolysis and mitochondrial oxidative phosphorylation

One of the hallmarks of cancer cells is their changed cellular metabolism. Cancer cells prefer to use glycolysis for ATP production and in this way, they elevate their glucose uptake to trigger glycolysis, a phenomenon known as Warburg effect [154]. In a variety of cancer cells lines such as ovarian and breast cancers, resveratrol is able to stimulate apoptosis and diminish the viability of cancer cells via decreasing glucose metabolism [155–157]. So, in suppressing the proliferation and malignancy of cancer cells, resveratrol induces metabolic reprogramming. The administration of resveratrol shifts cancer cell metabolism from glycolysis into mitochondrial respiration. This is followed by mitochondrial recruitment, stimulation of mitochondrial respiration, fatty acid oxidation, enhancing ROS production and subsequent activation of apoptosis via intrinsic pathway in cancer cells [158]. As it was mentioned, cancer cells apply Warburg effect to produce daughter cells and enhance their growth via generation of ATP, NADPH and anabolic building blocks [212–214]. It was first believed that Warburg effect occurs in cells that have mitochondrial oxidative phosphorylation defect, but it seems that Warburg effect also occurs in cells having competent oxidative

Table 1 Mitochondrial regulation by resveratrol in cancer therapy

Cancer cell line	Dose	Duration	Outcomes	Ref
B16F10 cells	0.1, 0.2, 0.5, 1, 2 and 10 µg/ml	24 h	Enhancing ROS generation subsequently induction of mitochondrial-mediated apoptosis	[221]
Mouse colon cancer cells CT26 tumor-bearing nude mice	2 mg/kg	5 h 35 days	Releasing cyt C into cytosol activation of caspase 3 and apoptotic cell death	[222]
Hepg2 cells xenografts in nude mice	1, 4, 8, 12 and 16 µg/ml	50 days	By down-regulation of PI3K/Akt pathway, Res-loaded NPs induced mitochondrial-mediated apoptosis	[223]
NCI-H460 cell line	-	24 h	Induction of mitochondrial-mediated apoptosis through NF-κB down-regulation	[224]
A549 cells	0.01, 0.1, 1, 5, 10, 20 and 50 µg/ml	24 h	Stimulation of apoptotic cell death	[225]
HepG2 (human hepatoma cells) and L-02 (human normal liver cells)	75, 100, 150 and 200 µM	3 h	Enhancing the level of ROS and induction of mitochondrial-mediated apoptosis	[144]
Human triple-negative breast cancer (MDA-MB-231), estrogen-receptor-positive breast cancer (MCF-7), cervix cancer (SiHa, HeLa), lung cancer (A549) and osteosarcoma (Saos-2) cells, and non-cancer human umbilical vein endothelial cells (HUEVC)	0.01, 0.1, 1, 10 and 200 µM	48 h	Promoting ROS generation and triggering apoptotic cell death	[145]
Human lung cancer cell lines, H838 and H520	40, 50, 60 and 70 µg/ml	24, 48 and 72 h	Enhancing the anti-tumor activity of cisplatin through mitochondrial dysfunction	[226]
TRAMP-C1, TRAMP-C2 and TRAMP-C3 cells	50 and 100 µM	16 h	Disruption of mitochondrial DNA induces apoptosis	[153]
SW620 colon cancer cell line	0, 5, 10, 20, 40, 80 and 160 µM	48 h	Shifting into fatty acid oxidation induces oxidative stress and apoptosis in cancer cells	[158]
A549 and HCC-15 cells	12.5, 25 and 50 µM	12 h	Sensitizing cancer cells into TRAIL-mediated apoptosis by induction of mitochondrial dysfunction	[171]
PC3 cancer cells	10 µM	48 h	By promoting mitochondrial fusion, Res suppresses cell division resulting in reduced proliferation of cancer cells	[177]
HeLa and Ea.hy926 cells	100 µM	36 h	Enhancing Ca ²⁺ uptake by mitochondria results in apoptotic cell death	[187]
Two breast cancer cell lines, MCF-7 and MDA-MB-231	10, 25 and 50 µM	24 and 48 h	Induction of mitochondrial-mediated apoptosis through Sirt1 up-regulation	[192]
HCT116 colon cancer cells, PC3 and LNCaP prostate cancer cells, and MDA-MB231 breast cancer cells	60 and 120 µM	0, 24 and 36 h	Inhibition of autophagy enhances mitochondrial-mediated apoptosis	[201]
Human cervical [76], colon (DLD1), breast (MCF-7), and liver (HepG2) cancer cell lines	0, 25, 50, 100, 150 and 200 µM	24 h	Triggering mitochondrial fission is related to reduced viability and proliferation of cancer cells	[178]
Human OC CAOV-3 cells	120 µM	48 h	Stimulation of autophagic and apoptotic cell death by inhibition of STAT3 and via the mitochondrial pathway	[205]
Prostate cancer cells	1, 10, 25, 50 and 100 µM	1, 3 and 4 h	By p66Shc-Ser66 phosphorylation and ERK1/2 dephosphorylation, Res induces mitochondrial oxidative stress and apoptosis to suppress the viability and proliferation of cancer cells	[227]
Human T-cell leukemia cell line, CEM; human lung carcinoma cell line, A549; Human T-cell leukemia cell line, Molt4; human cervix adenocarcinoma cell line, HeLa	1, 5, 10 and 20 µM	48 h	A novel Res based tubulin inhibitor reduces the malignancy of cancer cells by making a loss in mitochondrial membrane potential and apoptosis induction	[228]
Rat C6 glioma cell line	1, 10, 30, 50 and 100 µM	48 h	Stimulation of cell cycle arrest and apoptosis by targeting mitochondria and subsequently caspase-3	[229]
MCF-7, MDA-MB-231 and MCF-10A cells	50 µM	24 h	Induction of ROS-mediated mitochondrial dysfunction and consequently cancer cell death	[230]
Caco2 cells	10 µM	0, 8, 24 and 30 h	Inhibition of cancer cell growth by triggering glucose oxidation via increasing AMPK or CamKKB expression	[231]
HepG2 (human liver carcinoma) cell line	12.5, 25, 50, 100, 200, 400 and 800 µg/ml	3 days	Stimulation of apoptosis by upregulation of caspase-3 and caspase-9 through mitochondrial pathway	[232]
Three human oral squamous cell carcinoma (OSCC) cell lines, CAL-27, SCC15, and SCC25	0, 50, 100, 200, 300, 400 and 500 µM	72 h	By triggering mitochondrial apoptosis, Res inhibits EMT	[233]

Continued over

Table 1 Mitochondrial regulation by resveratrol in cancer therapy (Continued)

Cancer cell line	Dose	Duration	Outcomes	Ref
MCF7 and MDA-MB-231 cell lines	20 μ M	72 h	Induction of apoptosis through the mitochondrial pathway	[234]
Cancer cell lines Panc-1, Mia paca-2, CF pac-1, and BxPC-3	0, 50, 100, 150 and 200 μ M	24 h	By down-regulation of NAF-1, Res sensitizes cancer cells into apoptosis	[211]
HeLa human cervical cancer line	0, 5, 10, 20 and 40 μ mol/l	48 h	Stimulation of apoptosis through the mitochondrial pathway	[235]
Human breast cancer cell lines MCF-7 and MDA-MB-231 and lung cancer cell line H1299	100 μ M	24 h	Induction of apoptosis by reducing mitochondrial membrane potential	[236]
SCLC H446 cells	0, 10, 20, 30 and 40 μ g/ml	24 h	Sensitizing cancer cells to cisplatin therapy through the mitochondrial pathway of apoptosis	[237]
Prostate cancer cells	0, 10, 20, 30, 40 and 50 μ M	48 h	Res-loaded PLGA NPs enhanced ROS and induced mitochondrial-mediated apoptosis	[238]
Caco-2 cells (HTB-37TM)	0.1, 1, 10, 25, 50 and 100 μ M	48 h	Targeting mitochondrial membrane potential and induction of intrinsic pathway of apoptosis	[237]
DBTRG glioblastoma cells	50 μ M	24 h	Enhancing the efficacy of paclitaxel in chemotherapy by mitochondrial dysfunction and induction of apoptotic cell death	[239]
Glioblastoma A172 cell	0, 1, 5, 10 and 20 μ m/ml	-	Exposing cells into resveratrol is associated with a decrease in expression of AMPK and YAP. Inhibition of PAK2 enhances ROS production and inhibits AMPK/YAP axis, resulting in mitochondrial-mediated apoptosis	[53]




Figure 1. The involvement signaling network involved in stimulation of mitochondrial-mediated apoptosis by resveratrol

phosphorylation [215]. Attention has been directed toward suppressing glucose fermentation and triggering oxidative phosphorylation to inhibit cancer growth [216,217]. The hypoxia inducible factor-1 (HIF-1) is suggested to be involved in Warburg effect and its inhibition is a promising strategy in cancer therapy [218,219]. In prostate cancer cells, resveratrol supplementation induces apoptosis and cell cycle arrest by shifting cellular metabolism from glycolysis into mitochondrial oxidative phosphorylation. Resveratrol improves mitochondrial biogenesis, fusion and respiration by HIF-1 α down-regulation to stimulate cell cycle arrest in cancer cells [220]. These studies highlight the fact that resveratrol is able to target cellular metabolism of cancer cells and by enhancing oxidative phosphorylation

Table 2 Nanostrategies used for resveratrol delivery in targeting mitochondria in cancer therapy

Nanocarrier	Size (nm)	Zeta potential (mV)	Entrapment efficiency (%)	Cancer type	Major outcomes	Refs
Liposome	70	-9.78	82.58	Lung cancer	Selective targeting of mitochondria, enhancing the anti-tumor activity and induction of apoptotic cell death in cancer cells	[249]
Gelatin nanoparticle	294	-	-	Lung cancer	Stimulation of apoptosis and cell cycle arrest by down-regulation of Bcl-2 and NF- κ B, and up-regulation of caspases due to targeted delivery	[224]
Gold nanoparticle	39	-32.5	-	Liver cancer	Delivering resveratrol in cells and mitochondria and subsequent activation of mitochondrial apoptosis	[223]
Titanium disulfide nanosheet	123	-37.2	-	Colon cancer	Higher cytotoxicity compared resveratrol alone by reducing mitochondrial membrane potential, releasing cytochrome c and induction of intrinsic pathway of apoptosis	[222]
Polymeric nanoparticle	231.12	86.18	50-70	Prostate cancer	Resveratrol-loaded nanoparticles significantly enhance the ROS production in cancer cells and stimulate mitochondrial-mediated cell death	[238]

predisposes cancer cells into apoptosis. Table 1 summarizes the effect of resveratrol administration on mitochondria in cancer therapy.

Selective targeting of mitochondria in cancer therapy using nanoparticles (NPs)

Nanotechnology is a multidisciplinary field that can be used in different fields such as engineering, medicine and chemistry [240–242]. Nanoparticles are structures with size less than 100 nm with capability of enhancing the bioavailability of drugs by encapsulating them and protection against degradation [8,243]. Also, they can reduce the clearance of drugs by escaping from phagocytosis system. Nanoparticles have been used in the field of cancer therapy due to their capability in selective targeting cancer cells and enhancing the accumulation of anti-tumor drugs in cancer cells. Nanoparticles can be used for delivery of both genes and drugs in cancer therapy [244]. There have been efforts to target mitochondria using NPs. Notably, due to the negative charge of mitochondrial membranes of tumor cells, these NPs should have positive charges [245,246]. It seems that mitochondrial-targeted NPs have great therapeutic impacts [247–249]. Liposomes are one of the most important nanocarriers that can be applied in the delivery of small molecules and genes [250,251]. Liposomes have a number of great properties such as high biocompatibility and capability of encapsulating both hydrophilic and hydrophobic drugs [252,253]. Surface modification of liposomes can make them specific for targeting mitochondria. Dequalinium (DQA) and 4-carboxybutyl triphenylphosphonium bromide (TPP) are cations that can be used for surface modification of liposomes resulting in the preparation of liposomes with the capability of targeting negatively charged mitochondria [254–257]. Mitochondriotropic liposomes are promising candidates in enhancing the delivery of resveratrol into mitochondria. Resveratrol-loaded nanocarriers effectively deliver resveratrol into mitochondria of cancer cells. Resveratrol promotes the generation of ROS to depolarize the mitochondrial membrane resulting in apoptotic cell death [221]. Loading resveratrol on the mitochondrial-targeted titanium disulfide nanosheets is another potential strategy in cancer chemotherapy. These nanosheets effectively target mitochondria leading to the enhanced delivery of resveratrol. After exposure to near-infrared irradiation, the releasing of resveratrol occurs. Resveratrol diminishes the mitochondrial membrane potential to release cyt C into the cytoplasm. Subsequently, caspase 3 was induced by caspase 9 resulting in the stimulation of apoptotic cell death [222].

Gold and silver NPs are extensively used in biomedicine due to their minimal toxicity and high biocompatibility [258,259]. Gold NPs have demonstrated great potential in both immunotherapy and cancer therapy [260,261]. Loading resveratrol on gold NPs improves its anti-tumor activity both *in vitro* and *in vivo*. Resveratrol-loaded gold NPs significantly accumulate in mitochondria and mediate apoptosis. It was found that resveratrol-loaded gold NPs elevate the expression of caspase-8 and BAX, while they reduce the expression of pro-caspase-9 and pro-caspase-3.

Investigation of molecular signaling pathways reveal that this mitochondrial-mediated apoptosis is induced by down-regulation of PI3K/Akt pathway [223].

Polymeric NPs are capable of being used as nanocarriers for chemotherapeutic agents [262,263]. These NPs have shown great potential in accumulating in solid tumors via enhanced permeation retention (EPR) mechanism [264]. Resveratrol-loaded gelatin NPs can suppress the viability and proliferation of non-small cell lung cancer (NSCLC) cells by upregulation of BAX, p53, p21, caspase-3, and down-regulation of Bcl-2 and nuclear factor- κ B (NF- κ B) demonstrating the involvement of mitochondrial-mediated apoptosis [224]. NSCLC cells are sensitive to the mitochondrial-mediated apoptosis by resveratrol (Figure 1) [225]. Table 2 summarizes the nanocarriers used for delivery of resveratrol in targeting mitochondria in cancer therapy.

Conclusion and remarks

Plant-derived chemicals have demonstrated great potential in cancer therapy due to their capability in targeting various molecular pathways. In respect to the role of mitochondria in the induction of the intrinsic pathways of apoptosis, targeting this intracellular organelle is of importance in cancer therapy. Resveratrol is a naturally occurring compound that is capable of significantly reducing the viability and proliferation of cancer cells. Resveratrol is able to target mitochondria in cancer therapy. Primarily, resveratrol administration at a high amount enhances the concentration of ROS in mitochondria to stimulate mitochondrial dysfunction via making changes in the potential of OMM and opening the pores. As a consequence, cyt C releases into cytoplasm that triggers the caspase cascade resulting in apoptosis. A number of molecular signaling pathways are involved in mitochondrial regulation by resveratrol such as NF- κ B and Sirt1. A challenge faced in cancer therapy is the resistance of cancer cells into chemotherapy and resveratrol treatment improves the potential of chemotherapeutic agents by sensitizing cancer cells to apoptotic cell death. These effects of resveratrol on mitochondria remarkably reduce the viability and proliferation of cancer cells and inhibit colony formation by tumor cells. One of the common features of cancer cells is their uncontrollable growth and proliferation. Resveratrol can target cell cycle and stimulates cell cycle arrest in G1/S and G2/M phases of cell cycle by regulation of mitochondrial fusion and fission. Resveratrol induces mitochondrial fusion and fission via Mfn2 upregulation and PKM2 down-regulation, respectively, leading to reduced viability and proliferation of cancer cells via cell cycle arrest. Resveratrol elevates Ca^{2+} uptake by mitochondria to impair its proper function and sensitize cancer cells into apoptosis. Resveratrol positively affects Sirt1 expression to diminish mitochondrial respiration and viability of cancer cells. Resveratrol is able to provide connection between apoptosis and autophagy in cancer cells. By inhibition of STAT3, resveratrol stimulates apoptosis and autophagy in cancer cells to reduce their progression. Suppressing autophagy enhances resveratrol-mediated apoptosis in cancer cells. As a protein located on OMM, NAF-1 inhibition by resveratrol sensitizes cancer cells into apoptosis. In order to enhance the potential of resveratrol in targeting mitochondria and induction of apoptosis, NPs can be applied and several studies have shown the higher anti-tumor activity of resveratrol compared to resveratrol alone due to targeted delivery. This review discussed the different aspects of resveratrol and mitochondrial in cancer therapy. All of the studies are in agreement with efficacy of resveratrol in activation of mitochondrial-mediated apoptosis by targeting various molecular pathways. However, there are controversial data about the effect of resveratrol on mitochondrial oxidative phosphorylation. Some of the studies demonstrate that resveratrol impairs mitochondrial oxidative phosphorylation, while others hold the view that resveratrol enhances mitochondrial oxidative phosphorylation. Both of them are in line with that fact that resveratrol targets oxidative phosphorylation to induce apoptosis. However, more studies are needed to clarify the discussed issues.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work acknowledges the Department of Biotechnology (DBT), under its Ramalingaswami Fellowship number [BT/RLF/Re-entry/24/2014] and Science and Engineering Research Board under its ECRA scheme [SERB File No. ECR/2016/001519] award to Dr Manoj Garg.

Abbreviations

13-EBR, 13-ethylberberine; A β , amyloid- β ; AD, Alzheimer's disease; AMPK, AMP-activated protein kinase; Apaf-1, apoptotic protease activating factor 1; ATP, adenosine triphosphate; Bak, Bcl-2 antagonist/killer protein; Bax, Bcl-2 associated x protein; Bcl-2, B-cell lymphoma 2; cyt C, cytochrome C; DM, diabetes mellitus; DQA, dequalinium; EMT, epithelial-to-mesenchymal transition; EPR, enhanced permeation retention; ER, endoplasmic reticulum; FADD, Fas-associated protein with death domain; FoxO3, forkhead box O3; IMM, inner mitochondrial membrane; lncRNA, long non-coding RNA; Mfn2, mitofusion-2;

miR, microRNA; MMP, mitochondrial membrane potential; MOMP, mitochondrial outer membrane permeabilization; mtDNA, mitochondrial DNA; NAF-1, nutrient-deprivation autophagy factor 1; ND, neurological disorder; NF- κ B, nuclear factor- κ B; NP, nanoparticle; Nrf2, nuclear factor erythroid 2-related factor 2; NSCLC, non-small cell lung cancer; OMM, outer mitochondrial membrane; PAK2, P21-activated protein kinase 2; PARP, poly (ADP-ribose) polymerase; PD-1, programmed death-1; PTX, paclitaxel; Res-SLNs, Res-loaded solid lipid nanoparticles; ROCK, Rho-associated protein kinase; ROS, reactive oxygen species; SERCA, sarcoplasmic/endoplasmic reticulum Ca^{2+} ATPase; Sirt1, sirtuin 1; STAT, signal transducer and activator of transcription; TPP, 4-carboxybutyl triphenylphosphonium bromide; TRAF6, TNF-receptor associated factor 6; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; YAP, Yes-associated protein.

References

- Mortezaee, K., Najafi, M., Farhood, B., Ahmadi, A., Shabeeb, D. and Musa, A.E. (2019) Resveratrol as an adjuvant for normal tissues protection and tumor sensitization. *Curr. Cancer Drug Targets* **20**, 130–145
- Mortezaee, K., Potes, Y., Mirtavoos-Mahyari, H., Motevaseli, E., Shabeeb, D., Musa, A.E. et al. (2019) Boosting immune system against cancer by melatonin: A mechanistic viewpoint. *Life Sci.* **238**, 116960, <https://doi.org/10.1016/j.lfs.2019.116960>
- Mortezaee, K., Salehi, E., Mirtavoos-mahyari, H., Motevaseli, E., Najafi, M., Farhood, B. et al. (2019) Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. *J. Cell. Physiol.* **234**, 12537–12550, <https://doi.org/10.1002/jcp.28122>
- Mortezaee, K., Najafi, M., Farhood, B., Ahmadi, A., Potes, Y., Shabeeb, D. et al. (2019) Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. *Life Sci.* **228**, 228–241, <https://doi.org/10.1016/j.lfs.2019.05.009>
- Sun, L., Hu, Y., Mishra, A., Sreeharsha, N., Moktan, J.B., Kumar, P. et al. (2020) Protective role of poly(lactic-co-glycolic) acid nanoparticle loaded with resveratrol against isoproterenol-induced myocardial infarction. *Biofactors*, <https://doi.org/10.1002/biof.1611>
- Wu, C.W., Nakamoto, Y., Hisatome, T., Yoshida, S. and Miyazaki, H. (2020) Resveratrol and its dimers epsilon-viniferin and delta-viniferin in red wine protect vascular endothelial cells by a similar mechanism with different potency and efficacy. *Kaohsiung J. Med. Sci.*, <https://doi.org/10.1002/kjm2.12199>
- Wang, J., Zhang, Z., Fang, A., Wu, K., Chen, X., Wang, G. et al. (2020) Resveratrol Attenuates Inflammatory Bowel Disease in Mice by Regulating SUMO1. *Biol. Pharm. Bull.* **43**, 450–457, <https://doi.org/10.1248/bpb.b19-00786>
- Hu, Y., Wang, Z., Qiu, Y., Liu, Y., Ding, M. and Zhang, Y. (2019) Anti-miRNA21 and resveratrol-loaded polysaccharide-based mesoporous silica nanoparticle for synergistic activity in gastric carcinoma. *J. Drug Target.* **27**, 1135–1143, <https://doi.org/10.1080/1061186X.2019.1610766>
- Kolling, J., Kolling, J., Franceschi, I.D., Nishihira, V.S.K., Baldissera, M.D., Pinto, C.G. et al. (2019) Resveratrol and resveratrol-hydroxypropyl-beta-cyclodextrin complex recovered the changes of creatine kinase and Na⁺, K⁺-ATPase activities found in the spleen from streptozotocin-induced diabetic rats. *An. Acad. Bras. Cienc.* **91**, e20181330, <https://doi.org/10.1590/0001-3765201920181330>
- Khafaga, A.F., Noreldin, A.E. and Taha, A.E. (2019) The adaptogenic anti-ageing potential of resveratrol against heat stress-mediated liver injury in aged rats: Role of HSP70 and NF- κ B signalling. *J. Therm. Biol.* **83**, 8–21, <https://doi.org/10.1016/j.jtherbio.2019.04.012>
- Ahmadi, Y., Mahmoudi, N., Yousefi, B. and Karimian, A. (2019) The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; new functions for statins. *Pharmacol. Res.* 104621
- Hoseini, A., Namazi, G., Farrokhi, A., Reiner, Z., Aghadavod, E., Bahmani, F. et al. (2019) The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. *Food Funct.* **10**, 6042–6051
- Jing, Y., Hu, T., Lin, C., Xiong, Q., Liu, F., Yuan, J. et al. (2019) Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor alpha-mediated pathway in L02 cells. *Eur. J. Pharmacol.* **855**, 216–226, <https://doi.org/10.1016/j.ejphar.2019.05.019>
- Jang, Y.G., Go, R.E., Hwang, K.A. and Choi, K.C. (2019) Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway. *J. Steroid Biochem. Mol. Biol.* **192**, 105406, <https://doi.org/10.1016/j.jsbmb.2019.105406>
- Jie, K.Y., Wei, C.L., Min, Z., Ping, G.J., Ying, W., Dan, Z. et al. (2019) Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel. *Front. Biosci. (Landmark Edition)* **24**, 1452–1461
- Martinez-Martinez, D., Soto, A., Gil-Araujo, B., Gallego, B., Chiloeches, A. and Lasa, M. (2019) Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin. *Food Chem. Toxicol.* **124**, 273–279, <https://doi.org/10.1016/j.fct.2018.12.014>
- Means, J.C., Lopez, A.A. and Koulen, P. (2020) Resveratrol Protects Optic Nerve Head Astrocytes from Oxidative Stress-Induced Cell Death by Preventing Caspase-3 Activation, Tau Dephosphorylation at Ser(422) and Formation of Misfolded Protein Aggregates. *Cell. Mol. Neurobiol.*, <https://doi.org/10.1007/s10571-019-00781-6>
- Sun, X.Y., Dong, Q.X., Zhu, J., Sun, X., Zhang, L.F., Qiu, M. et al. (2019) Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy. *Curr. Alzheimer Res.* **16**, 710–722, <https://doi.org/10.2174/1567205016666190801153751>
- Chen, Y., Shi, G.W., Liang, Z.M., Sheng, S.Y., Shi, Y.S., Peng, L. et al. (2019) Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice. *Mol. Med. Reports* **19**, 3783–3790
- Szkudelska, K., Okulicz, M., Hertig, I. and Szkudelski, T. (2020) Resveratrol ameliorates inflammatory and oxidative stress in type 2 diabetic Goto-Kakizaki rats. *Biomed. Pharmacother.* **125**, 110026, <https://doi.org/10.1016/j.biopha.2020.110026>
- Aamir, K., Khan, H.U., Sethi, G., Hossain, M.A. and Arya, A. (2019) Wnt signaling mediates TLR pathway and promote unrestrained adipogenesis and metaflammation: Therapeutic targets for obesity and type 2 diabetes. *Pharmacol. Res.* **152**, 104602
- Jaladin-Fincati, J.R., Pavarotti, M., Frendo-Cumbo, S., Bilan, P.J. and Klip, A. (2017) Update on GLUT4 vesicle traffic: a cornerstone of insulin action. *Trends Endocrinol. Metab.* **28**, 597–611, <https://doi.org/10.1016/j.tem.2017.05.002>

- 23 Mohseni, R., ArabSadeghabadi, Z., Ziamajidi, N., Abbasalipourkabir, R. and RezaeiFarimani, A. (2019) Oral administration of resveratrol-loaded solid lipid nanoparticle improves insulin resistance through targeting expression of SNARE proteins in adipose and muscle tissue in rats with type 2 diabetes. *Nanoscale Res. Lett.* **14**, 227, <https://doi.org/10.1186/s11671-019-3042-7>
- 24 Bahmanzadeh, M., Goodarzi, M.T., Rezaei Farimani, A., Fathi, N. and Alizadeh, Z. Resveratrol supplementation improves DNA integrity and sperm parameters in streptozotocin–nicotinamide-induced type 2 diabetic rats. *Andrologia* **2019**, e13313
- 25 Singh, C.K., Ndiaye, M.A. and Ahmad, N. (2015) Resveratrol and cancer: Challenges for clinical translation. *Biochim. Biophys. Acta (BBA)-Mol. Basis Disease* **1852**, 1178–1185, <https://doi.org/10.1016/j.bbdis.2014.11.004>
- 26 Amri, A., Chaumeil, J., Sfar, S. and Charrueau, C. (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? *J. Control. Release* **158**, 182–193, <https://doi.org/10.1016/j.jconrel.2011.09.083>
- 27 Minnelli, C., Laudadio, E., Galeazzi, R., Barucca, G., Notarstefano, V., Cantarini, M. et al. (2020) Encapsulation of a Neutral Molecule into a Cationic Clay Material: Structural Insight and Cytotoxicity of Resveratrol/Layered Double Hydroxide/BSA Nanocomposites. *Nanomaterials* **10**, 33, <https://doi.org/10.3390/nano10010033>
- 28 Vervandier-Fasseur, D. and Latruffe, N. (2019) The Potential Use of Resveratrol for Cancer Prevention. *Molecules* **24**, 4506, <https://doi.org/10.3390/molecules24244506>
- 29 Shoukry, H.S., Ammar, H.I., Rashed, L.A., Zikri, M.B., Shamaa, A.A., Abu-Al Rub, E. et al. (2017) Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity. *PLoS One* **12**, e0181535, <https://doi.org/10.1371/journal.pone.0181535>
- 30 Huang, W., Li, G., Qiu, J., Gonzalez, P. and Challa, P. (2013) Protective effects of resveratrol in experimental retinal detachment. *PLoS One* **8**, e75735, <https://doi.org/10.1371/journal.pone.0075735>
- 31 Buhrmann, C., Shayan, P., Goel, A. and Shakibaei, M. (2017) Resveratrol regulates colorectal cancer cell invasion by modulation of focal adhesion molecules. *Nutrients* **9**, 1073, <https://doi.org/10.3390/nu9101073>
- 32 Shu, X.-H., Li, H., Sun, Z., Wu, M.-L., Ma, J.-X., Wang, J.-M. et al. (2010) Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. *Biochem. Pharmacol.* **79**, 1516–1525, <https://doi.org/10.1016/j.bcp.2010.01.022>
- 33 Wu, M.-L., Li, H., Yu, L.-J., Chen, X.-Y., Kong, Q.-Y., Song, X. et al. (2014) Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. *PLoS One* **9**, e89806, <https://doi.org/10.1371/journal.pone.0089806>
- 34 Xue, S., Xiao-Hong, S., Lin, S., Jie, B., Li-Li, W., Jia-Yao, G. et al. (2016) Lumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas. *Oncotarget* **7**, 75790, <https://doi.org/10.18632/oncotarget.12414>
- 35 Kuk, D.-H., Ha, E.-S., Ha, D.-H., Sim, W.-Y., Lee, S.-K., Jeong, J.-S. et al. (2019) Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach. *Pharmaceutics* **11**, 688, <https://doi.org/10.3390/pharmaceutics11120688>
- 36 Thipe, V.C., Amiri, K.P., Bloebaum, P., Karikachery, A.R., Khoobchandani, M., Katti, K.K. et al. (2019) Development of resveratrol-conjugated gold nanoparticles: Interrelationship of increased resveratrol corona on anti-tumor efficacy against breast, pancreatic and prostate cancers. *Int. J. Nanomed.* **14**, 4413, <https://doi.org/10.2147/IJN.S204443>
- 37 de Oliveira, M.T.P., de Sá Coutinho, D., de Souza, É.T., Guterres, S.S., Pohlmann, A.R., Silva, P.M.R., Martins, M.A. et al. (2019) Orally delivered resveratrol-loaded lipid-core nanocapsules ameliorate LPS-induced acute lung injury via the ERK and PI3K/Akt pathways. *Int. J. Nanomed.* **14**, 5215, <https://doi.org/10.2147/IJN.S200666>
- 38 Musazzi, U.M., Youm, I., Murowchick, J.B., Ezoulin, M.J. and Youan, B-BC (2014) Resveratrol-loaded nanocarriers: formulation, optimization, characterization and in vitro toxicity on cochlear cells. *Colloids Surf. B* **118**, 234–242, <https://doi.org/10.1016/j.colsurfb.2014.03.054>
- 39 Jung, K.-H., Lee, J.H., Park, J.W., Quach, C.H.T., Moon, S.-H., Cho, Y.S. et al. (2015) Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth in vitro and in vivo. *Int. J. Pharm.* **478**, 251–257, <https://doi.org/10.1016/j.ijpharm.2014.11.049>
- 40 Jose, S., Anju, S., Cinu, T., Aleykutty, N., Thomas, S. and Souto, E. (2014) In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. *Int. J. Pharm.* **474**, 6–13, <https://doi.org/10.1016/j.ijpharm.2014.08.003>
- 41 Pandita, D., Kumar, S., Poonia, N. and Lather, V. (2014) Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. *Food Res. Int.* **62**, 1165–1174, <https://doi.org/10.1016/j.foodres.2014.05.059>
- 42 Pund, S., Thakur, R., More, U. and Joshi, A. (2014) Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy. *Colloids Surf. B* **120**, 110–117, <https://doi.org/10.1016/j.colsurfb.2014.05.016>
- 43 Amri, A., Le Clanche, S., Thérond, P., Bonnefont-Rousselot, D., Borderie, D., Lai-Kuen, R. et al. (2014) Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death. *Eur. J. Pharm. Biopharm.* **86**, 418–426, <https://doi.org/10.1016/j.ejpb.2013.10.015>
- 44 Pangen, R., Sharma, S., Mustafa, G., Ali, J. and Baboota, S. (2014) Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress. *Nanotechnology* **25**, 485102, <https://doi.org/10.1088/0957-4484/25/48/485102>
- 45 Zhou, J., Zhou, M., Yang, F.-F., Liu, C.-Y., Pan, R.-L., Chang, Q. et al. (2015) Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by labrasol containing nanoemulsions. *Mol. Pharm.* **12**, 1084–1095, <https://doi.org/10.1021/mp5005838>
- 46 Caddeo, C., Manconi, M., Fadda, A.M., Lai, F., Lampis, S., Diez-Sales, O. et al. (2013) Nanocarriers for antioxidant resveratrol: formulation approach, vesicle self-assembly and stability evaluation. *Colloids Surf. B* **111**, 327–332, <https://doi.org/10.1016/j.colsurfb.2013.06.016>
- 47 Isailović, B.D., Kostić, I.T., Zvonar, A., Đorđević, V.B., Gašperlin, M., Nedović, V.A. et al. (2013) Resveratrol loaded liposomes produced by different techniques. *Innovative Food Sci. Emerg. Technol.* **19**, 181–189, <https://doi.org/10.1016/j.ifset.2013.03.006>
- 48 Hao, J., Zhao, J., Zhang, S., Tong, T., Zhuang, Q., Jin, K. et al. (2016) Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. *Colloids Surf. B* **147**, 376–386, <https://doi.org/10.1016/j.colsurfb.2016.08.011>
- 49 Zupančič, Š., Lavrič, Z. and Kristl, J. (2015) Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature. *Eur. J. Pharm. Biopharm.* **93**, 196–204, <https://doi.org/10.1016/j.ejpb.2015.04.002>

- 50 Guo, X., Zhao, Z., Chen, D., Qiao, M., Wan, F., Cun, D. et al. (2019) Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. *Asian J. Pharm. Sci.* **14**, 78–85, <https://doi.org/10.1016/j.ajps.2018.03.002>
- 51 Siedlecka-Kroplewska, K., Wozniak, M. and Kmiec, Z. (2019) The wine polyphenol resveratrol modulates autophagy and induces apoptosis in MOLT-4 and HL-60 human leukemia cells. *J. Physiol. Pharmacol.: An Off. J. Polish Physiological Soc.* **70**
- 52 Xu, G., Chen, J., Wang, G., Xiao, J., Zhang, N., Chen, Y. et al. (2020) Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway. *Mol. Therapy Oncolytics* **16**, 124–133, <https://doi.org/10.1016/j.omto.2019.12.010>
- 53 Xing, J., Wang, Z., Xu, H., Liu, C., Wei, Z., Zhao, L. et al. (2020) Pak2 inhibition promotes resveratrol-mediated glioblastoma A172 cell apoptosis via modulating the AMPK-YAP signaling pathway. *J. Cell. Physiol.*, <https://doi.org/10.1002/jcp.29515>
- 54 Wu, J., Li, Y.T., Tian, X.T., Liu, Y.S., Wu, M.L., Li, P.N. et al. (2020) STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells. *Cancer Biomarkers: Section A Dis. Markers*, <https://doi.org/10.3233/CBM-191010>
- 55 Khusbu, F.Y., Zhou, X., Roy, M., Chen, F.Z., Cao, Q. and Chen, H.C. (2020) Resveratrol induces depletion of TRAF6 and suppresses prostate cancer cell proliferation and migration. *Int. J. Biochem. Cell Biol.* **118**, 105644, <https://doi.org/10.1016/j.biocel.2019.105644>
- 56 Senthil Kumar, C., Thangam, R., Mary, S.A., Kannan, P.R., Arun, G. and Madhan, B. (2020) Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells. *Carbohydr. Polym.* **231**, 115682, <https://doi.org/10.1016/j.carbpol.2019.115682>
- 57 Li, D., Wang, G., Jin, G., Yao, K., Zhao, Z., Bie, L. et al. (2019) Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway. *Int. J. Mol. Med.* **43**, 630–640
- 58 Lee, K.W., Chung, K.S., Lee, J.H., Choi, J.H., Choi, S.Y., Kim, S. et al. (2019) Resveratrol analog, N-(4-methoxyphenyl)-3,5-dimethoxybenzamide induces G2/M phase cell cycle arrest and apoptosis in HeLa human cervical cancer cells. *Food Chem. Toxicol.* **124**, 101–111, <https://doi.org/10.1016/j.fct.2018.11.062>
- 59 Liu, X., Li, H., Wu, M.L., Wu, J., Sun, Y., Zhang, K.L. et al. (2019) Resveratrol Reverses Retinoic Acid Resistance of Anaplastic Thyroid Cancer Cells via Demethylating CRABP2 Gene. *Front. Endocrinol.* **10**, 734, <https://doi.org/10.3389/fendo.2019.00734>
- 60 Verdura, S., Cuyas, E., Cortada, E., Brunet, J., Lopez-Bonet, E., Martin-Castillo, B. et al. (2020) Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. *Aging* **11**, <https://doi.org/10.18632/aging.102646>
- 61 Tong, J., Gao, J., Liu, Q., He, C., Zhao, X., Qi, Y. et al. (2019) Resveratrol-derived excited postsynaptic potentiation specifically via PKC β -NMDA receptor mediation. *Pharmacol. Res.* 104618, <https://doi.org/10.1016/j.phrs.2019.104618>
- 62 Lin, C.C., Chin, Y.T., Shih, Y.J., Chen, Y.R., Chung, Y.Y., Lin, C.Y. et al. (2019) Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells. *J. Dental Sci.* **14**, 255–262, <https://doi.org/10.1016/j.jds.2019.01.013>
- 63 Wang, G., Xie, X., Yuan, L., Qiu, J., Duan, W., Xu, B. et al. (2019) Resveratrol ameliorates rheumatoid arthritis via activation of SIRT1-Nrf2 signaling pathway. *Biofactors*, <https://doi.org/10.1002/biof.1599>
- 64 Chen, K.Y., Chen, C.C., Chang, Y.C. and Chang, M.C. (2019) Resveratrol induced premature senescence and inhibited epithelial-mesenchymal transition of cancer cells via induction of tumor suppressor Rad9. *PLoS One* **14**, e0219317, <https://doi.org/10.1371/journal.pone.0219317>
- 65 Chatterjee, B., Ghosh, K. and Kanade, S.R. (2019) Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21(CIP1) in human breast cancer cell lines. *Biofactors* **45**, 818–829, <https://doi.org/10.1002/biof.1544>
- 66 Oh, H.N., Lee, M.H., Kim, E., Kwak, A.W., Yoon, G., Cho, S.S. et al. (2020) Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET. *Biomolecules* **10**, 297, <https://doi.org/10.3390/biom10020297>
- 67 El Khoury, M., Haykal, T., Hodroj, M.H., Najem, S.A., Sarkis, R., Taleb, R.I. et al. (2020) Malva pseudolavatera Leaf Extract Promotes ROS Induction Leading to Apoptosis in Acute Myeloid Leukemia Cells In Vitro. *Cancers (Basel)* **12**, <https://doi.org/10.3390/cancers12020435>
- 68 Zhuang, Y., Wu, H., Wang, X., He, J., He, S. and Yin, Y. (2019) Resveratrol Attenuates Oxidative Stress-Induced Intestinal Barrier Injury through PI3K/Akt-Mediated Nrf2 Signaling Pathway. *Oxidative Med. Cell. Longevity* **2019**, 7591840, <https://doi.org/10.1155/2019/7591840>
- 69 Chen, Y., Zheng, Z., Li, C., Pan, Y., Tang, X. and Wang, X.J. (2019) Synthetic Imine Resveratrol Analog 2-Methoxyl-3,6-Dihydroxyl-IRA Ameliorates Colitis by Activating Protective Nrf2 Pathway and Inhibiting NLRP3 Expression. *Oxidative Med. Cell. Longevity* **2019**, 7180284, <https://doi.org/10.1155/2019/7180284>
- 70 Xu, G., Zhao, X., Fu, J. and Wang, X. (2019) Resveratrol increase myocardial Nrf2 expression in type 2 diabetic rats and alleviate myocardial ischemia/reperfusion injury (MIRI). *Ann. Palliative Med.* **8**, 565–575, <https://doi.org/10.21037/apm.2019.11.25>
- 71 Hosseini, H., Teimouri, M., Shabani, M., Koushki, M., Babaei Khorzoughi, R., Namvarjah, F. et al. (2019) Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. *Int. J. Biochem. Cell Biol.* **119**, 105667, <https://doi.org/10.1016/j.biocel.2019.105667>
- 72 Quadri, M.M., Fatima, S.S., Che, R.C. and Zhang, A.H. (2019) Mitochondria and Renal Fibrosis. *Adv. Exp. Med. Biol.* **1165**, 501–524, https://doi.org/10.1007/978-981-13-8871-2_25
- 73 Ventura-Clapier, R., Piquereau, J., Veksler, V. and Garnier, A. (2019) Estrogens, Estrogen Receptors Effects on Cardiac and Skeletal Muscle Mitochondria. *Front. Endocrinol.* **10**, 557, <https://doi.org/10.3389/fendo.2019.00557>
- 74 Becker, T. and Wagner, R. (2018) Mitochondrial outer membrane channels: emerging diversity in transport processes. *Bioessays* **40**, 1800013, <https://doi.org/10.1002/bies.201800013>
- 75 Burke, P.J. (2017) Mitochondria, Bioenergetics and Apoptosis in Cancer. *Trends Cancer* **3**, 857–870, <https://doi.org/10.1016/j.trecan.2017.10.006>
- 76 Abate, M., Festa, A., Falco, M., Lombardi, A., Luce, A. and Grimaldi, A. (2019) Mitochondria as playmakers of apoptosis, autophagy and senescence. *Seminars in cell & developmental biology: 2019*, Elsevier
- 77 Perkins, G.A. and Ellisman, M.H. (2016) Remodeling of mitochondria in apoptosis. *Mitochondria and Cell Death*, pp. 85–110, Springer
- 78 Otera, H. and Mihara, K. (2012) Mitochondrial dynamics: functional link with apoptosis. *Int. J. Cell Biol.* **2012**, <https://doi.org/10.1155/2012/821676>

- 79 Yen, H.-Y., Tsao, C.-W., Lin, Y.-W., Kuo, C.-C., Tsao, C.-H. and Liu, C.-Y. (2019) Regulation of carcinogenesis and modulation through Wnt/ β -catenin signaling by curcumin in an ovarian cancer cell line. *Sci. Rep.* **9**, 1–14, <https://doi.org/10.1038/s41598-019-53509-3>
- 80 Zhang, N., Sheng, M., Wu, M., Zhang, X., Ding, Y., Lin, Y. et al. (2019) Berberine protects steatotic donor undergoing liver transplantation via inhibiting endoplasmic reticulum stress-mediated reticulophagy. *Exp. Biol. Med.* **244**, 1–10, <https://doi.org/10.1177/1535370219878651>
- 81 Matarrese, P., Tieri, P., Anticoli, S., Ascione, B., Conte, M., Franceschi, C. et al. (2019) X-chromosome-linked miR548am-5p is a key regulator of sex disparity in the susceptibility to mitochondria-mediated apoptosis. *Cell Death. Dis.* **10**, 673, <https://doi.org/10.1038/s41419-019-1888-3>
- 82 Tsai, I.J., Lin, W.C., Yang, Y.H., Tseng, Y.L., Lin, Y.H., Chou, C.H. et al. (2019) High Concentration of C5a-Induced Mitochondria-Dependent Apoptosis in Murine Kidney Endothelial Cells. *Int. J. Mol. Sci.* **20**, 4465, <https://doi.org/10.3390/ijms20184465>
- 83 Estaquier, J., Vallette, F., Vayssiere, J.-L. and Mignotte, B. (2012) The mitochondrial pathways of apoptosis. *Advances in Mitochondrial Medicine*, pp. 157–183, Springer
- 84 Zhang, M., Zheng, J., Nussinov, R. and Ma, B. (2017) Release of cytochrome C from Bax pores at the mitochondrial membrane. *Sci. Rep.* **7**, 2635, <https://doi.org/10.1038/s41598-017-02825-7>
- 85 Jeena, M., Kim, S., Jin, S. and Ryu, J.-H. (2020) Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy. *Cancers* **12**, 4, <https://doi.org/10.3390/cancers12010004>
- 86 Baines, C. (2010) Role of the mitochondrion in programmed necrosis. *Front. Physiol.* **1**, 156, <https://doi.org/10.3389/fphys.2010.00156>
- 87 Giorgi, C., Agnoletto, C., Bononi, A., Bonora, M., De Marchi, E., Marchi, S. et al. (2012) Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. *Mitochondrion* **12**, 77–85, <https://doi.org/10.1016/j.mito.2011.07.004>
- 88 Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell* **144**, 646–674, <https://doi.org/10.1016/j.cell.2011.02.013>
- 89 Porter, A.G. and Jänicke, R.U. (1999) Emerging roles of caspase-3 in apoptosis. *Cell Death Differ.* **6**, 99, <https://doi.org/10.1038/sj.cdd.4400476>
- 90 Lamkanfi, M. and Kanneganti, T.-D. (2010) Caspase-7: a protease involved in apoptosis and inflammation. *Int. J. Biochem. Cell Biol.* **42**, 21–24, <https://doi.org/10.1016/j.biocel.2009.09.013>
- 91 Elmore, S. (2007) Apoptosis: a review of programmed cell death. *Toxicol. Pathol.* **35**, 495–516, <https://doi.org/10.1080/01926230701320337>
- 92 Jayakiran, M. (2015) Apoptosis-biochemistry: a mini review. *J. Clin. Exp. Pathol.* **5**, 1–4, <https://doi.org/10.4172/2161-0681.1000205>
- 93 Young, M.L. and Franklin, J.L. (2019) The mitochondria-targeted antioxidant MitoQ inhibits memory loss, neuropathology, and extends lifespan in aged 3xTg-AD mice. *Mol. Cell. Neurosci.* 103409, <https://doi.org/10.1016/j.mcn.2019.103409>
- 94 Ku, S.-K., Kwak, S. and Bae, J.-S. (2014) Orientin inhibits high glucose-induced vascular inflammation in vitro and in vivo. *Inflammation* **37**, 2164–2173, <https://doi.org/10.1007/s10753-014-9950-x>
- 95 Law, B.N.T., Ling, A.P.K., Koh, R.Y., Chye, S.M. and Wong, Y.P. (2014) Neuroprotective effects of orientin on hydrogen peroxide-induced apoptosis in SH-SY5Y cells. *Mol. Med. Reports* **9**, 947–954, <https://doi.org/10.3892/mmr.2013.1878>
- 96 Thangaraj, K., Balasubramanian, B., Park, S., Natesan, K., Liu, W. and Manju, V. (2019) Orientin Induces G0/G1 Cell Cycle Arrest and Mitochondria Mediated Intrinsic Apoptosis in Human Colorectal Carcinoma HT29 Cells. *Biomolecules* **9**, 418, <https://doi.org/10.3390/biom9090418>
- 97 Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global cancer statistics, 2012. *CA Cancer J. Clin.* **65**, 87–108, <https://doi.org/10.3322/caac.21262>
- 98 McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M. et al. (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet* **383**, 2127–2135
- 99 Deloch, L., Derer, A., Hartmann, J., Frey, B., Fietkau, R. and Gaipl, U.S. (2016) Modern radiotherapy concepts and the impact of radiation on immune activation. *Front. Oncol.* **6**, 141, <https://doi.org/10.3389/fonc.2016.00141>
- 100 Lee, D.-U., Kang, Y.J., Park, M.K., Lee, Y.S., Seo, H.G., Kim, T.S. et al. (2003) Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF- α , iNOS, and IL-12 production in LPS-stimulated macrophages. *Life Sci.* **73**, 1401–1412, [https://doi.org/10.1016/S0024-3205\(03\)00435-1](https://doi.org/10.1016/S0024-3205(03)00435-1)
- 101 Lee, D.U., Ko, Y.S., Kim, H.J. and Chang, K.C. (2017) 13-Ethylberberine reduces HMGB1 release through AMPK activation in LPS-activated RAW264. 7 cells and protects endotoxemic mice from organ damage. *Biomed. Pharmacother.* **86**, 48–56, <https://doi.org/10.1016/j.biopha.2016.11.099>
- 102 Ozben, T. (2007) Oxidative stress and apoptosis: impact on cancer therapy. *J. Pharm. Sci.* **96**, 2181–2196, <https://doi.org/10.1002/jps.20874>
- 103 Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S.S. et al. (2013) Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS One* **8**, e81162, <https://doi.org/10.1371/journal.pone.0081162>
- 104 Jin, H., Ko, Y.S., Park, S.W., Chang, K.C. and Kim, H.J. (2019) 13-Ethylberberine Induces Apoptosis through the Mitochondria-Related Apoptotic Pathway in Radiotherapy-Resistant Breast Cancer Cells. *Molecules* **24**, 2448, <https://doi.org/10.3390/molecules24132448>
- 105 Lamoral-Théys, D., Andolfi, A., Van Goetsenoven, G., Cimmino, A., Le Calvé, B., Wauthoz, N. et al. (2009) Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure–activity relationship and mechanistic insight. *J. Med. Chem.* **52**, 6244–6256, <https://doi.org/10.1021/jm901031h>
- 106 Cao, Z., Yu, D., Fu, S., Zhang, G., Pan, Y., Bao, M. et al. (2013) Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. *Toxicol. Lett.* **218**, 174–185, <https://doi.org/10.1016/j.toxlet.2013.01.018>
- 107 Zeng, H., Fu, R., Yan, L. and Huang, J. (2017) Lycorine induces apoptosis of A549 cells via AMPK-mammalian target of rapamycin (mTOR)-S6K signaling pathway. *Med. Sci. Monit.* **23**, 2035, <https://doi.org/10.12659/MSM.900742>
- 108 Totsukawa, G., Yamakita, Y., Yamashiro, S., Hartshorne, D.J., Sasaki, Y. and Matsumura, F. (2000) Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. *J. Cell Biol.* **150**, 797–806, <https://doi.org/10.1083/jcb.150.4.797>

- 109 Shi, J. and Wei, L. (2007) Rho kinase in the regulation of cell death and survival. *Arch. Immunol. Ther. Exp. (Warsz.)* **55**, 61, <https://doi.org/10.1007/s00005-007-0009-7>
- 110 Liu, S. (2011) The ROCK signaling and breast cancer metastasis. *Mol. Biol. Rep.* **38**, 1363–1366, <https://doi.org/10.1007/s11033-010-0238-4>
- 111 Whatcott, C.J., Ng, S., Barrett, M.T., Hostetter, G., Von Hoff, D.D. and Han, H. (2017) Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. *PLoS One* **12**, e0183871, <https://doi.org/10.1371/journal.pone.0183871>
- 112 Liu, W.Y., Tang, Q., Zhang, Q., Hu, C.P., Huang, J.B., Sheng, F.F. et al. (2019) Lycorine Induces Mitochondria-Dependent Apoptosis in Hepatoblastoma HepG2 Cells Through ROCK1 Activation. *Front. Pharmacol.* **10**, 651, <https://doi.org/10.3389/fphar.2019.00651>
- 113 Ma, Y.S., Yao, C.N., Liu, H.C., Yu, F.S., Lin, J.J., Lu, K.W. et al. (2018) Quercetin induced apoptosis of human oral cancer SAS cells through mitochondria and endoplasmic reticulum mediated signaling pathways. *Oncol. Lett.* **15**, 9663–9672
- 114 Harini, L., Srivastava, S., Gnanakumar, G.P., Karthikeyan, B., Ross, C., Krishnakumar, V. et al. (2019) An ingenious non-spherical mesoporous silica nanoparticle cargo with curcumin induces mitochondria-mediated apoptosis in breast cancer (MCF-7) cells. *Oncotarget* **10**, 1193–1208, <https://doi.org/10.18632/oncotarget.26623>
- 115 Najafi, M., Shayesteh, M.R.H., Mortezaee, K., Farhood, B. and Haghi-Aminjan, H. (2019) The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. *Life Sci.* 117173
- 116 Shabeeb, D., Musa, A.E., Keshavarz, M., Hassanzadeh, G., Hadian, M.R., Nowrouzi, A. et al. (2020) Melatonin Ameliorates Radiation-induced Sciatic Nerve Injury. *Lett. Drug Des. Discovery* **17**, 21–30, <https://doi.org/10.2174/1570180816666190617160434>
- 117 Funamoto, M., Shimizu, K., Sunagawa, Y., Katanasaka, Y., Miyazaki, Y., Kakeya, H. et al. (2019) Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus. *J. Diabetes Res.* **2019**, 1–8, <https://doi.org/10.1155/2019/8208237>
- 118 Huminiecki, L., Atanasov, A.G. and Horbanczuk, J. (2020) Etiology of atherosclerosis informs choice of animal models and tissues for initial functional genomic studies of resveratrol. *Pharmacol. Res.* 104598, <https://doi.org/10.1016/j.phrs.2019.104598>
- 119 Liu, J., Yan, Y., Liu, J., Wang, Y. and Wang, X. (2019) Curcumin prevents experimental autoimmune encephalomyelitis by inhibiting proliferation and effector CD4+ T cell activation. *Eur. Rev. Med. Pharmacol. Sci.* **23**, 9108–9116
- 120 Huang, Y., Dan, N., Dan, W. and Zhao, W. (2019) Reinforcement of Polycaprolactone/Chitosan with Nanoclay and Controlled Release of Curcumin for Wound Dressing. *ACS Omega* **4**, 22292–22301, <https://doi.org/10.1021/acsomega.9b02217>
- 121 Aliasgharzadeh, A., Farhood, B., Amini, P., Saffar, H., Motevaseli, E., Rezapoor, S. et al. (2019) Melatonin Attenuates Upregulation of Duox1 and Duox2 and Protects against Lung Injury following Chest Irradiation in Rats. *Cell J. (Yakhteh)* **12**, 1–7
- 122 Tian, N., Gao, Y., Wang, X., Wu, X., Zou, D., Zhu, Z. et al. (2018) Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy. *Drug Des. Dev. Ther.* **12**, 2195, <https://doi.org/10.2147/DDDT.S167405>
- 123 Zhu, D., Shao, M., Yang, J., Fang, M., Liu, S., Lou, D. et al. (2020) Curcumin Enhances Radiosensitization of Nasopharyngeal Carcinoma via Mediating Regulation of Tumor Stem-like Cells by a CircRNA Network. *J. Cancer* **11**, 2360–2370, <https://doi.org/10.7150/jca.39511>
- 124 Costa, M.C., Lima, T.F.O., Arcaro, C.A., Inacio, M.D., Batista-Duharte, A., Carlos, I.Z. et al. (2020) Trigonelline and curcumin alone, but not in combination, counteract oxidative stress and inflammation and increase glycation product detoxification in the liver and kidney of mice with high-fat diet-induced obesity. *J. Nutr. Biochem.* **76**, 108303, <https://doi.org/10.1016/j.jnutbio.2019.108303>
- 125 Yu, Y., Sun, J., Wang, R., Liu, J., Wang, P. and Wang, C. (2019) Curcumin Management of Myocardial Fibrosis and its Mechanisms of Action: A Review. *Am. J. Chin. Med.* **47**, 1675–1710, <https://doi.org/10.1142/S0192415X19500861>
- 126 Dehghani, S., Dalirfardouei, R., Jafari Najaf Abadi, M.H., Ebrahimi Nik, M., Jaafari, M.R. and Mahdipour, E. (2020) Topical application of curcumin regulates the angiogenesis in diabetic-impaired cutaneous wound. *Cell Biochem. Funct.*, <https://doi.org/10.1002/cbf.3500>
- 127 Zhou, Q., Wu, X., Liu, Y., Wang, X., Ling, X., Ge, H. et al. (2019) Curcumin improves asthenozoospermia by inhibiting reactive oxygen species reproduction through nuclear factor erythroid 2-related factor 2 activation. *Andrologia* **52**, e13491
- 128 Akaishi, T., Yamamoto, S. and Abe, K. (2020) The Synthetic Curcumin Derivative CNB-001 Attenuates Thrombin-Stimulated Microglial Inflammation by Inhibiting the ERK and p38 MAPK Pathways. *Biol. Pharm. Bull.* **43**, 138–144, <https://doi.org/10.1248/bpb.b19-00699>
- 129 Lai, K.-C., Chueh, F.-S., Hsiao, Y.-T., Cheng, Z.-Y., Lien, J.-C., Liu, K.-C. et al. (2019) Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo. *Toxicol. Appl. Pharmacol.* **382**, 114734, <https://doi.org/10.1016/j.taap.2019.114734>
- 130 Kuttikrishnan, S., Siveen, K.S., Prabhu, K.S., Khan, A.Q., Ahmed, E.I., Akhtar, S. et al. (2019) Curcumin induces apoptotic cell death via inhibition of PI3-Kinase/AKT pathway in B-precursor acute lymphoblastic leukemia. *Front. Oncol.* **9**, 1–13, <https://doi.org/10.3389/fonc.2019.00484>
- 131 Hasan, W., Kori, R.K., Jain, J., Yadav, R.S. and Jat, D. (2019) Neuroprotective effects of mitochondria-targeted curcumin against rotenone-induced oxidative damage in cerebellum of mice. *J. Biochem. Mol. Toxicol.* **34**, e22416
- 132 Saunders, I.T., Mir, H., Kapur, N. and Singh, S. (2019) Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways. *Cancer Cell Int.* **19**, 98, <https://doi.org/10.1186/s12935-019-0820-3>
- 133 Lin, L., Liu, Y., Fu, S., Qu, C., Li, H. and Ni, J. (2019) Inhibition of Mitochondrial Complex Function-The Hepatotoxicity Mechanism of Emodin Based on Quantitative Proteomic Analyses. *Cells* **8**, 263, <https://doi.org/10.3390/cells8030263>
- 134 Fan, J., Zhang, K., Jin, Y., Li, B., Gao, S., Zhu, J. et al. (2019) Pharmacological effects of berberine on mood disorders. *J. Cell. Mol. Med.* **23**, 21–28, <https://doi.org/10.1111/jcmm.13930>
- 135 Li, Z., Geng, Y.-N., Jiang, J.-D. and Kong, W.-J. (2014) Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. *Evidence-Based Complementary and Alternative Med.* **2014**, 1–13
- 136 Cheng, Y. and Ji, Y. (2019) Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity. *J. Control. Release* **318**, 38–49
- 137 Zhao, C., Su, P., Lv, C., Guo, L., Cao, G., Qin, C. et al. (2019) Berberine Alleviates Amyloid β -Induced Mitochondrial Dysfunction and Synaptic Loss. *Oxidative Med. Cell. Longevity* **2019**, 1–12, <https://doi.org/10.1155/2019/7593608>

- 138 Li, Z., Jiang, T., Lu, Q., Xu, K., He, J., Xie, L. et al. (2019) Berberine attenuated the cytotoxicity induced by t-BHP via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells. *Cell. Mol. Neurobiol.* 1–16
- 139 Hussain, S.P., Hofseth, L.J. and Harris, C.C. (2003) Radical causes of cancer. *Nat. Rev. Cancer* **3**, 276, <https://doi.org/10.1038/nrc1046>
- 140 Khan, N., Afaq, F. and Mukhtar, H. (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. *Antioxid. Redox Signal.* **10**, 475–510, <https://doi.org/10.1089/ars.2007.1740>
- 141 Fan, G.J., Jin, X.L., Qian, Y.P., Wang, Q., Yang, R.T., Dai, F. et al. (2009) Hydroxycinnamic acids as DNA-cleaving agents in the presence of Cu(II) ions: mechanism, structure–activity relationship, and biological implications. *Chem. Eur. J.* **15**, 12889–12899, <https://doi.org/10.1002/chem.200901627>
- 142 León-González, A.J., Auger, C. and Schini-Kerth, V.B. (2015) Pro-oxidant activity of polyphenols and its implication on cancer chemoprevention and chemotherapy. *Biochem. Pharmacol.* **98**, 371–380, <https://doi.org/10.1016/j.bcp.2015.07.017>
- 143 D'Souza, L.C., Mishra, S., Chakraborty, A., Shekher, A., Sharma, A. and Gupta, S.C. (2019) Oxidative stress and cancer development: Are non-coding RNAs the missing links? *Antioxidants Redox Signal.*, (ja)
- 144 Dai, F., Wang, Q., Fan, G.-J., Du, Y.-T. and Zhou, B. (2018) ROS-driven and preferential killing of HepG2 over L-02 cells by a short-term cooperation of Cu(II) and a catechol-type resveratrol analog. *Food Chem.* **250**, 213–220, <https://doi.org/10.1016/j.foodchem.2018.01.069>
- 145 Rodríguez-Enriquez, S., Pacheco-Velázquez, S.C., Marín-Hernández, Á., Gallardo-Pérez, J.C., Robledo-Cadena, D.X., Hernández-Reséndiz, I. et al. (2019) Resveratrol inhibits cancer cell proliferation by impairing oxidative phosphorylation and inducing oxidative stress. *Toxicol. Appl. Pharmacol.* **370**, 65–77, <https://doi.org/10.1016/j.taap.2019.03.008>
- 146 Juan, I., M.E., Wenzel, U., Daniel, H. and Planas, J.M. (2008) Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. *J. Agric. Food Chem.* **56**, 4813–4818, <https://doi.org/10.1021/jf800175a>
- 147 Lucas, I.K. and Kolodziej, H. (2015) Trans-resveratrol induces apoptosis through ROS-triggered mitochondria-dependent pathways in A549 human lung adenocarcinoma epithelial cells. *Planta Med.* **81**, 1038–1044
- 148 Park, J.-W., Choi, W.-g., Lee, P.-j., Chung, S.-w., Kim, B.-s., Chung, H.-t et al. (2017) The novel resveratrol derivative 3, 5-diethoxy-3', 4'-dihydroxy-trans-stilbene induces mitochondrial ROS-mediated ER stress and cell death in human hepatoma cells in vitro. *Acta Pharmacol. Sin.* **38**, 1486, <https://doi.org/10.1038/aps.2017.106>
- 149 Santandreu, F.M., Valle, A., Oliver, J. and Roca, P. (2011) Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. *Cell. Physiol. Biochem.* **28**, 219–228, <https://doi.org/10.1159/00031733>
- 150 Zheng, X., Jia, B., Tian, X.-T., Song, X., Wu, M.-L., Kong, Q.-Y. et al. (2018) Correlation of reactive oxygen species levels with resveratrol sensitivities of anaplastic thyroid cancer cells. *Oxidative Med. Cell. Longevity* **2018**, 1–13, <https://doi.org/10.1155/2018/6235417>
- 151 Hurlle, J.M. (2014) Regenerative versus destructive cell death in developing systems and tissue homeostasis. *Bioessays*, <https://doi.org/10.1002/bies.201400149>
- 152 Donato, A.L., Huang, Q., Liu, X., Li, F., Zimmerman, M.A. and Li, C.-Y. (2014) Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. *J. Invest. Dermatol.* **134**, 1686–1692, <https://doi.org/10.1038/jid.2014.18>
- 153 Kumar, S., Eroglu, E., Stokes, Ill, J.A., Scisum-Gunn, K., Saldanha, S.N., Singh, U.P. et al. (2017) Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. *Oncotarget* **8**, 20895, <https://doi.org/10.18632/oncotarget.14947>
- 154 Warburg, O. (1956) On the origin of cancer cells. *Science* **123**, 309–314, <https://doi.org/10.1126/science.123.3191.309>
- 155 Kueck, A., Opiari Jr, A.W., Griffith, K.A., Tan, L., Choi, M., Huang, J. et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. *Gynecol. Oncol.* **107**, 450–457, <https://doi.org/10.1016/j.ygyno.2007.07.065>
- 156 Gomez, L.S., Zancan, P., Marcondes, M.C., Ramos-Santos, L., Meyer-Fernandes, J.R., Sola-Penna, M. et al. (2013) Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. *Biochimie* **95**, 1336–1343, <https://doi.org/10.1016/j.biochi.2013.02.013>
- 157 Gwak, H., Haegeman, G., Tsang, B.K. and Song, Y.S. (2015) Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. *Mol. Carcinog.* **54**, 1529–1540, <https://doi.org/10.1002/mc.22227>
- 158 del Mar Blanquer-Rosselló, M., Hernández-López, R., Roca, P., Oliver, J. and Valle, A. (2017) Resveratrol induces mitochondrial respiration and apoptosis in SW620 colon cancer cells. *Biochimica et Biophysica Acta (BBA)-General Subjects* **1861**, 431–440, <https://doi.org/10.1016/j.bbagen.2016.10.009>
- 159 Takashina, M., Inoue, S., Tomihara, K., Tomita, K., Zhao, Q.-L. et al. (2017) Different effect of resveratrol to induction of apoptosis depending on the type of human cancer cells. *Int. J. Oncol.* **50**, 787–797, <https://doi.org/10.3892/ijo.2017.3859>
- 160 Wang, B., Liu, J. and Gong, Z. (2015) Resveratrol induces apoptosis in K562 cells via the regulation of mitochondrial signaling pathways. *Int. J. Clin. Exp. Med.* **8**, 16926–16933
- 161 Gao, Y., He, C., Ran, R., Zhang, D., Li, D., Xiao, P.G. et al. (2015) The resveratrol oligomers, cis- and trans-gnetin H, from *Paeonia suffruticosa* seeds inhibit the growth of several human cancer cell lines. *J. Ethnopharmacol.* **169**, 24–33, <https://doi.org/10.1016/j.jep.2015.03.074>
- 162 Boyer, J.Z., Jandova, J., Janda, J., Vleugels, F.R., Elliott, D.A. and Sligh, J.E. (2012) Resveratrol-sensitized UVA induced apoptosis in human keratinocytes through mitochondrial oxidative stress and pore opening. *J. Photochem. Photobiol. B* **113**, 42–50, <https://doi.org/10.1016/j.jphotobiol.2012.04.013>
- 163 Kumar, S., Stokes, Ill, J., Singh, U.P., Scisum-Gunn, K., Singh, R., Manne, U. et al. (2017) Prolonged exposure of resveratrol induces reactive superoxide species-independent apoptosis in murine prostate cells. *Tumor Biol.* **39**, 1010428317715039, <https://doi.org/10.1177/1010428317715039>
- 164 Lin, X., Wu, G., Huo, W.Q., Zhang, Y. and Jin, F.S. (2012) Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. *Int. J. Urol.: Off. J. Japanese Urological Assoc.* **19**, 757–764, <https://doi.org/10.1111/j.1442-2042.2012.03024.x>
- 165 Lu, C.X., Sun, J.H. and Wu, C.L. (2016) Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells. *Zhongguo Zhong Yao Za Zhi* **41**, 476–483

- 166 Ou, X., Chen, Y., Cheng, X., Zhang, X. and He, Q. (2014) Potentiation of resveratrol-induced apoptosis by matrine in human hepatoma HepG2 cells. *Oncol. Rep.* **32**, 2803–2809, <https://doi.org/10.3892/or.2014.3512>
- 167 Rahman, M.A., Kim, N.H., Kim, S.H., Oh, S.M. and Huh, S.O. (2012) Antiproliferative and cytotoxic effects of resveratrol in mitochondria-mediated apoptosis in rat b103 neuroblastoma cells. *The Korean J. Physiol. Pharmacol.: Off. J. Korean Physiological Soc. Korean Soc. Pharmacol.* **16**, 321–326, <https://doi.org/10.4196/kjpp.2012.16.5.321>
- 168 Stuckey, D.W. and Shah, K. (2013) TRAIL on trial: preclinical advances in cancer therapy. *Trends Mol. Med.* **19**, 685–694, <https://doi.org/10.1016/j.molmed.2013.08.007>
- 169 Wang, S. (2010) TRAIL: a sword for killing tumors. *Curr. Med. Chem.* **17**, 3309–3317, <https://doi.org/10.2174/092986710793176285>
- 170 Kandasamy, K., Srinivasula, S.M., Alnemri, E.S., Thompson, C.B., Korsmeyer, S.J., Bryant, J.L. et al. (2003) Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. *Cancer Res.* **63**, 1712–1721
- 171 Rasheduzzaman, M., Jeong, J.-K. and Park, S.-Y. (2018) Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF- κ B signaling. *Life Sci.* **208**, 208–220, <https://doi.org/10.1016/j.lfs.2018.07.035>
- 172 Zhao, H., Niu, Q., Li, X., Liu, T., Xu, Y., Han, H. et al. (2012) Long-term resveratrol consumption protects ovariectomized rats chronically treated with D-galactose from developing memory decline without effects on the uterus. *Brain Res.* **1467**, 67–80, <https://doi.org/10.1016/j.brainres.2012.05.040>
- 173 Rehman, J., Zhang, H.J., Toth, P.T., Zhang, Y., Marsboom, G., Hong, Z. et al. (2012) Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. *FASEB J.* **26**, 2175–2186, <https://doi.org/10.1096/fj.11-196543>
- 174 Taguchi, N., Ishihara, N., Jofuku, A., Oka, T. and Mihara, K. (2007) Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. *J. Biol. Chem.* **282**, 11521–11529, <https://doi.org/10.1074/jbc.M607279200>
- 175 Mitra, K., Wunder, C., Roysam, B., Lin, G. and Lippincott-Schwartz, J. (2009) A hyperfused mitochondrial state achieved at G1–S regulates cyclin E buildup and entry into S phase. *Proc. Natl. Acad. Sci.* **106**, 11960–11965, <https://doi.org/10.1073/pnas.0904875106>
- 176 Yan, Y., Ma, Z., Zhu, J., Zeng, M., Liu, H. and Dong, Z. (2020) miR-214 represses Mitofusin-2 to promote renal tubular apoptosis in ischemic acute kidney injury. *Am. J. Physiol. Ren. Physiol.* **318**, F878–F887, <https://doi.org/10.1152/ajprenal.00567.2019>
- 177 Robb, E.L., Moradi, F., Maddalena, L.A., Valente, A.J., Fonseca, J. and Stuart, J.A. (2017) Resveratrol stimulates mitochondrial fusion by a mechanism requiring mitofusin-2. *Biochem. Biophys. Res. Commun.* **485**, 249–254, <https://doi.org/10.1016/j.bbrc.2017.02.102>
- 178 Wu, H., Wang, Y., Wu, C., Yang, P., Li, H. and Li, Z. (2016) Resveratrol induces cancer cell apoptosis through MiR-326/PKM2-mediated ER stress and mitochondrial fission. *J. Agric. Food Chem.* **64**, 9356–9367, <https://doi.org/10.1021/acs.jafc.6b04549>
- 179 Dolfi, S.C., Chan, LL-Y, Qiu, J., Tedeschi, P.M., Bertino, J.R., Hirshfield, K.M. et al. (2013) The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. *Cancer Metab.* **1**, 20, <https://doi.org/10.1186/2049-3002-1-20>
- 180 Wang, W.-A., Groenendyk, J. and Michalak, M. (2014) Endoplasmic reticulum stress associated responses in cancer. *Biochim. Biophys. Acta* **1843**, 2143–2149, <https://doi.org/10.1016/j.bbamcr.2014.01.012>
- 181 Cárdenas, C., Müller, M., McNeal, A., Lovy, A., Jaña, F., Bustos, G. et al. (2016) Selective vulnerability of cancer cells by inhibition of Ca²⁺ transfer from endoplasmic reticulum to mitochondria. *Cell Rep.* **14**, 2313–2324, <https://doi.org/10.1016/j.celrep.2016.02.030>
- 182 Vishnu, N., Jadoon Khan, M., Karsten, F., Groschner, L.N., Waldeck-Weiermair, M., Rost, R. et al. (2014) ATP increases within the lumen of the endoplasmic reticulum upon intracellular Ca²⁺ release. *Mol. Biol. Cell* **25**, 368–379, <https://doi.org/10.1091/mbc.e13-07-0433>
- 183 Denton, R.M. (2009) Regulation of mitochondrial dehydrogenases by calcium ions. *Biochim. Biophys. Acta (BBA)-Bioenergetics* **1787**, 1309–1316, <https://doi.org/10.1016/j.bbabi.2009.01.005>
- 184 Gerencser, A.A., Chinopoulos, C., Birket, M.J., Jastroch, M., Vitelli, C., Nicholls, D.G. et al. (2012) Quantitative measurement of mitochondrial membrane potential in cultured cells: calcium-induced de- and hyperpolarization of neuronal mitochondria. *J. Physiol.* **590**, 2845–2871, <https://doi.org/10.1113/jphysiol.2012.228387>
- 185 Malli, R., Frieden, M., Osibow, K. and Graier, W.F. (2003) Mitochondria efficiently buffer subplasmalemmal Ca²⁺ elevation during agonist stimulation. *J. Biol. Chem.* **278**, 10807–10815, <https://doi.org/10.1074/jbc.M212971200>
- 186 Hajnóczky, G., Csordás, G., Das, S., García-Pérez, C., Saotome, M., Roy, S.S. et al. (2006) Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca²⁺ uptake in apoptosis. *Cell Calcium* **40**, 553–560, <https://doi.org/10.1016/j.ceca.2006.08.016>
- 187 Madreiter-Sokolowski, C.T., Gottschalk, B., Parichatikanond, W., Eroglu, E., Klec, C., Waldeck-Weiermair, M. et al. (2016) Resveratrol specifically kills cancer cells by a devastating increase in the Ca²⁺ coupling between the greatly tethered endoplasmic reticulum and mitochondria. *Cell. Physiol. Biochem.* **39**, 1404–1420, <https://doi.org/10.1159/000447844>
- 188 Chalkiadaki, A. and Guarente, L. (2015) The multifaceted functions of sirtuins in cancer. *Nat. Rev. Cancer* **15**, 608, <https://doi.org/10.1038/nrc3985>
- 189 Lu, J., Zhang, L., Chen, X., Lu, Q., Yang, Y., Liu, J. et al. (2014) SIRT1 counteracted the activation of STAT3 and NF- κ B to repress the gastric cancer growth. *Int. J. Clin. Exp. Med.* **7**, 5050
- 190 Bosch-Presegué, L. and Vaquero, A. (2011) The dual role of sirtuins in cancer. *Genes Cancer* **2**, 648–662, <https://doi.org/10.1177/1947601911417862>
- 191 Brenmoehl, J. and Hoeflich, A. (2013) Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. *Mitochondrion* **13**, 755–761, <https://doi.org/10.1016/j.mito.2013.04.002>
- 192 Deus, C.M., Serafim, T.L., Magalhães-Novais, S., Vilaça, A., Moreira, A.C., Sardão, V.A. et al. (2017) Sirtuin 1-dependent resveratrol cytotoxicity and pro-differentiation activity on breast cancer cells. *Arch. Toxicol.* **91**, 1261–1278, <https://doi.org/10.1007/s00204-016-1784-x>
- 193 Hazari, Y., Bravo-San Pedro, J.M., Hetz, C., Galluzzi, L. and Kroemer, G. (2020) Autophagy in hepatic adaptation to stress. *J. Hepatol.* **72**, 183–196, <https://doi.org/10.1016/j.jhep.2019.08.026>
- 194 Kuang, H., Tan, C.Y., Tian, H.Z., Liu, L.H., Yang, M.W., Hong, F.F. et al. (2020) Exploring the bi-directional relationship between autophagy and Alzheimer's disease. *CNS Neurosci. Ther.* **26**, 155–166

- 195 Zhou, B., Liu, J., Kang, R., Klionsky, D.J., Kroemer, G. and Tang, D. (2019) Ferroptosis is a type of autophagy-dependent cell death. *Seminars in cancer biology*: 2019, Elsevier
- 196 Yang, Y. and Klionsky, D.J. (2020) Autophagy and disease: unanswered questions. *Cell Death Differentiation* **27**, 858–871
- 197 Guo, H., Ren, H., Li, J., Hao, M., Hao, J., Ren, H. et al. (2020) TIPE2 suppressed cisplatin resistance by inducing autophagy via mTOR signalling pathway. *Exp. Mol. Pathol.* 104367, <https://doi.org/10.1016/j.yexmp.2020.104367>
- 198 Pan, Z., Wu, C., Li, Y., Li, H., An, Y., Wang, G. et al. (2019) LncRNA DANCER silencing inhibits SOX5-mediated progression and autophagy in osteosarcoma via regulating miR-216a-5p. *Biomed. Pharmacother.* **122**, 109707, <https://doi.org/10.1016/j.biopha.2019.109707>
- 199 Rong, L., Li, Z., Leng, X., Li, H., Ma, Y., Chen, Y. et al. (2019) Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. *Biomed. Pharmacother.* **122**, 109726, <https://doi.org/10.1016/j.biopha.2019.109726>
- 200 Xiong, H., Shen, J., Chen, Z., Yang, J., Xie, B., Jia, Y. et al. (2020) H19/let7/Lin28 ceRNA network mediates autophagy inhibiting epithelial-mesenchymal transition in breast cancer. *Int. J. Oncol.* **56**, 794–806
- 201 Prabhu, V., Srivastava, P., Yadav, N., Amadori, M., Schneider, A., Seshadri, A. et al. (2013) Resveratrol depletes mitochondrial DNA and inhibition of autophagy enhances resveratrol-induced caspase activation. *Mitochondrion* **13**, 493–499, <https://doi.org/10.1016/j.mito.2012.10.010>
- 202 Tettweiler, G., Blaquiere, J.A., Wray, N.B. and Verheyen, E.M. (2019) Hipk is required for JAK/STAT activity during development and tumorigenesis. *PLoS One* **14**, e0226856, <https://doi.org/10.1371/journal.pone.0226856>
- 203 Yang, G., Lyu, L., Wang, X., Bao, L., Lyu, B. and Lin, Z. (2019) Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway. *Pulm. Pharmacol. Ther.* **56**, 69–74, <https://doi.org/10.1016/j.pupt.2019.03.011>
- 204 Chang, C., Zhao, Y., Song, G. and She, K. (2018) Resveratrol protects hippocampal neurons against cerebral ischemia-reperfusion injury via modulating JAK/ERK/STAT signaling pathway in rats. *J. Neuroimmunol.* **315**, 9–14, <https://doi.org/10.1016/j.jneuroim.2017.11.015>
- 205 Zhong, L., Zhang, Y., Wu, M., Liu, Y., Zhang, P., Chen, X. et al. (2016) Resveratrol and STAT inhibitor enhance autophagy in ovarian cancer cells. *Cell Death Discovery* **2**, 15071, <https://doi.org/10.1038/cddiscovery.2015.71>
- 206 Holt, S.H., Darash-Yahana, M., Sohn, Y.S., Song, L., Karmi, O., Tamir, S. et al. (2016) Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells. *J. Cell Sci.* **129**, 155–165, <https://doi.org/10.1242/jcs.178293>
- 207 Chen, Y.-F., Kao, C.-H., Kirby, R. and Tsai, T.-F. (2009) Cisd2 mediates mitochondrial integrity and life span in mammals. *Autophagy* **5**, 1043–1045, <https://doi.org/10.4161/auto.5.7.9351>
- 208 Chen, Y.F., Wu, C.Y., Kirby, R., Kao, C.H. and Tsai, T.F. (2010) A role for the Cisd2 gene in lifespan control and human disease. *Ann. N. Y. Acad. Sci.* **1201**, 58–64, <https://doi.org/10.1111/j.1749-6632.2010.05619.x>
- 209 Liu, L., Xia, M., Wang, J., Zhang, W., Zhang, Y. and He, M. (2014) Cisd2 expression is a novel marker correlating with pelvic lymph node metastasis and prognosis in patients with early-stage cervical cancer. *Med. Oncol.* **31**, 183, <https://doi.org/10.1007/s12032-014-0183-5>
- 210 Sohn, Y.-S., Tamir, S., Song, L., Michaeli, D., Matouk, I., Conlan, A.R. et al. (2013) NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. *Proc. Natl. Acad. Sci.* **110**, 14676–14681, <https://doi.org/10.1073/pnas.1313198110>
- 211 Cheng, L., Yan, B., Chen, K., Jiang, Z., Zhou, C., Cao, J. et al. (2018) Resveratrol-induced downregulation of NAF-1 enhances the sensitivity of pancreatic cancer cells to gemcitabine via the ROS/Nrf2 signaling pathways. *Oxidative Med. Cell. Longevity* **2018**, 1–17, <https://doi.org/10.1155/2018/9482018>
- 212 Diaz-Ruiz, R., Rigoulet, M. and Devin, A. (2011) The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. *Biochim. Biophys. Acta (BBA)-Bioenergetics* **1807**, 568–576, <https://doi.org/10.1016/j.bbabi.2010.08.010>
- 213 Pavlova, N.N. and Thompson, C.B. (2016) The emerging hallmarks of cancer metabolism. *Cell Metab.* **23**, 27–47, <https://doi.org/10.1016/j.cmet.2015.12.006>
- 214 Koppenol, W.H. and Bounds, P.L. (2009) The Warburg effect and metabolic efficiency: re-crunching the numbers. *Science* **324**, 1029–1033
- 215 Yu, K.-D. and Shao, Z.-M. (2011) The two faces of autophagy and the pathological underestimation of DCIS. *Nat. Rev. Cancer* **11**, 618–618, <https://doi.org/10.1038/nrc2950-c1>
- 216 Vr, F., St-Pierre, J. and Leder, P. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* **9**, 425–434
- 217 Le, A., Cooper, C.R., Gouw, A.M., Dinavahi, R., Maitra, A., Deck, L.M. et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc. Natl. Acad. Sci.* **107**, 2037–2042, <https://doi.org/10.1073/pnas.0914433107>
- 218 Greer, S.N., Metcalf, J.L., Wang, Y. and Ohh, M. (2012) The updated biology of hypoxia-inducible factor. *EMBO J.* **31**, 2448–2460, <https://doi.org/10.1038/emboj.2012.125>
- 219 Masoud, G.N. and Li, W. (2015) HIF-1 α pathway: role, regulation and intervention for cancer therapy. *Acta Pharmaceutica Sinica B* **5**, 378–389, <https://doi.org/10.1016/j.apsb.2015.05.007>
- 220 Fonseca, J., Moradi, F., Maddalena, L.A., Ferreira-Tollstadius, B., Selim, S. and Stuart, J.A. (2019) Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1. *Oncol. Lett.* **17**, 697–705
- 221 Kang, J.H. and Ko, Y.T. (2019) Enhanced Subcellular Trafficking of Resveratrol Using Mitochondriotropic Liposomes in Cancer Cells. *Pharmaceutics* **11**, 423, <https://doi.org/10.3390/pharmaceutics11080423>
- 222 Xiang, S., Zhang, K., Yang, G., Gao, D., Zeng, C. and He, M. (2019) Mitochondria-Targeted and Resveratrol-Loaded Dual-Function Titanium Disulfide Nanosheets for Photothermal-Triggered Tumor Chemotherapy. *Nanoscale Res. Lett.* **14**, 211, <https://doi.org/10.1186/s11671-019-3044-5>
- 223 Zhang, D., Zhang, J., Zeng, J., Li, Z., Zuo, H., Huang, C. et al. (2019) Nano-gold loaded with resveratrol enhance the anti-hepatoma effect of resveratrol in vitro and in vivo. *J. Biomed. Nanotechnol.* **15**, 288–300, <https://doi.org/10.1166/jbn.2019.2682>

- 224 Karthikeyan, S., Hoti, S.L. and Prasad, N.R. (2015) Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small cell lung cancer cells. *Biomed. Pharmacother.* **70**, 274–282, <https://doi.org/10.1016/j.biopha.2015.02.006>
- 225 Q-s, Zhao, L-I, H.u., Z-d, Wang, Z-p, L.i., A-w, Wang and Liu, J. (2017) Resveratrol-loaded folic acid-grafted dextran stearate submicron particles exhibits enhanced antitumor efficacy in non-small cell lung cancers. *Mater. Sci. Engineer.: C* **72**, 185–191
- 226 Ma, L., Li, W., Wang, R., Nan, Y., Wang, Q., Liu, W. et al. (2015) Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis. *Int. J. Oncol.* **47**, 1460–1468, <https://doi.org/10.3892/ijco.2015.3124>
- 227 Conte, A., Procaccini, C., Iannelli, P., Kisslinger, A., De Amicis, F., Pierantoni, G. et al. (2015) Effects of Resveratrol on p66Shc phosphorylation in cultured prostate cells. *Translational Medicine@ UniSa* **13**, 47
- 228 Thomas, E., Gopalakrishnan, V., Hegde, M., Kumar, S., Karki, S.S., Raghavan, S.C. et al. (2016) A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. *Sci. Rep.* **6**, 34653, <https://doi.org/10.1038/srep34653>
- 229 Zielińska-Przyjemka, M., Kaczmarek, M., Krajka-Kuźniak, V., Luczak, M. and Baer-Dubowska, W. (2017) The effect of resveratrol, its naturally occurring derivatives and tannic acid on the induction of cell cycle arrest and apoptosis in rat C6 and human T98G glioma cell lines. *Toxicol. in Vitro* **43**, 69–75, <https://doi.org/10.1016/j.tiv.2017.06.004>
- 230 Dewangan, J., Tandon, D., Srivastava, S., Verma, A.K., Yapuri, A. and Rath, S.K. (2017) Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells. *Apoptosis* **22**, 1246–1259, <https://doi.org/10.1007/s10495-017-1394-y>
- 231 Saunier, E., Antonio, S., Regazzetti, A., Auzeil, N., Laprévotte, O., Shay, J.W. et al. (2017) Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells. *Sci. Rep.* **7**, 6945, <https://doi.org/10.1038/s41598-017-07006-0>
- 232 Olugbami, J.O., Damoiseaux, R., France, B., Onibiyo, E.M., Gbadegehin, M.A., Sharma, S. et al. (2017) A comparative assessment of antiproliferative properties of resveratrol and ethanol leaf extract of *Anogeissus leiocarpus* (DC) Guill and Perr against HepG2 hepatocarcinoma cells. *BMC Complement. Alternative Med.* **17**, 381, <https://doi.org/10.1186/s12906-017-1873-2>
- 233 Kim, S.-E., Shin, S.-H., Lee, J.-Y., Kim, C.-H., Chung, I.-K., Kang, H.-M. et al. (2018) Resveratrol induces mitochondrial apoptosis and inhibits epithelial-Mesenchymal transition in oral squamous cell carcinoma cells. *Nutr. Cancer* **70**, 125–135, <https://doi.org/10.1080/01635581.2018.1397708>
- 234 Mirzapour, P., Khazaei, M.R., Moradi, M.T. and Khazaei, M. (2018) Apoptosis induction in human breast cancer cell lines by synergic effect of raloxifene and resveratrol through increasing proapoptotic genes. *Life Sci.* **205**, 45–53, <https://doi.org/10.1016/j.lfs.2018.04.035>
- 235 Li, W., Shi, Y., Wang, R., Pan, L., Ma, L. and Jin, F. (2018) Resveratrol promotes the sensitivity of small-cell lung cancer H446 cells to cisplatin by regulating intrinsic apoptosis. *Int. J. Oncol.* **53**, 2123–2130
- 236 Ji, S., Zheng, Z., Liu, S., Ren, G., Gao, J., Zhang, Y. et al. (2018) Resveratrol promotes oxidative stress to drive DLC1 mediated cellular senescence in cancer cells. *Exp. Cell Res.* **370**, 292–302, <https://doi.org/10.1016/j.yexcr.2018.06.031>
- 237 Stornio, C.E. and Moreno, J.J. (2018) Resveratrol analogs with antioxidant activity inhibit intestinal epithelial cancer Caco-2 cell growth by modulating arachidonic acid cascade. *J. Agric. Food Chem.* **67**, 819–828, <https://doi.org/10.1021/acs.jafc.8b05982>
- 238 Nassir, A.M., Shahzad, N., Ibrahim, I.A., Ahmad, I., Md, S. and Ain, M.R. (2018) Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. *Saudi Pharmaceutical J.* **26**, 876–885, <https://doi.org/10.1016/j.jsps.2018.03.009>
- 239 Öztürk, Y., Günaydn, C., Yalçın, F., Nazroğlu, M. and Baidy, N. (2019) Resveratrol Enhances Apoptotic and Oxidant Effects of Paclitaxel through TRPM2 Channel Activation in DBTRG Glioblastoma Cells. *Oxidative Med. Cell. Longevity* **2019**, 1–14, <https://doi.org/10.1155/2019/4619865>
- 240 Miri, A., Mahdinejad, N., Ebrahimi, O., Khatami, M. and Sarani, M. (2019) Zinc oxide nanoparticles: Biosynthesis, characterization, antifungal and cytotoxic activity. *Mater. Sci. Eng.: C* **104**, 109981, <https://doi.org/10.1016/j.msec.2019.109981>
- 241 Akhtartavan, S., Karimi, M., Karimian, K., Azarpira, N., Khatami, M. and Heli, H. (2019) Evaluation of a self-nanoemulsifying docetaxel delivery system. *Biomed. Pharmacother.* **109**, 2427–2433, <https://doi.org/10.1016/j.biopha.2018.11.110>
- 242 Warriar, V.U., Makandar, A.I., Garg, M., Sethi, G., Kant, R., Pal, J.K. et al. (2019) Engineering anti-cancer nanovaccine based on antigen cross-presentation. *Biosci. Rep.* **39**, 1–19, <https://doi.org/10.1042/BSR20193220>
- 243 Miri, A., Khatami, M., Ebrahimi, O. and Sarani, M. (2020) Cytotoxic and antifungal studies of biosynthesized zinc oxide nanoparticles using extract of *Prosopis farcta* fruit. *Green Chem. Lett. Rev.* **13**, 27–33, <https://doi.org/10.1080/17518253.2020.1717005>
- 244 Kardani, A., Yaghoobi, H., Alibakhshi, A. and Khatami, M. Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer. *J. Cell. Physiol.*
- 245 Xie, C., Chang, J., Hao, X.-D., Yu, J.-M., Liu, H.-R. and Sun, X. (2013) Mitochondrial-targeted prodrug cancer therapy using a rhodamine B labeled fluorinated docetaxel. *Eur. J. Pharm. Biopharm.* **85**, 541–549, <https://doi.org/10.1016/j.ejpb.2013.06.008>
- 246 Zhang, X.Y. and Zhang, P.-Y. (2016) Mitochondria targeting nano agents in cancer therapeutics. *Oncol. Lett.* **12**, 4887–4890, <https://doi.org/10.3892/ol.2016.5302>
- 247 Patel, N.R., Hatziantoniou, S., Georgopoulos, A., Demetzos, C., Torchilin, V.P., Weissig, V. et al. (2010) Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. *J. Liposome Res.* **20**, 244–249, <https://doi.org/10.3109/08982100903347931>
- 248 Yamada, Y. and Harashima, H. (2013) Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier. *Mitochondrion* **13**, 526–532, <https://doi.org/10.1016/j.mito.2012.09.001>
- 249 Wang, X.-X., Li, Y.-B., Yao, H.-J., Ju, R.-J., Zhang, Y., Li, R.-J. et al. (2011) The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. *Biomaterials* **32**, 5673–5687, <https://doi.org/10.1016/j.biomaterials.2011.04.029>
- 250 Kang, J.H., Battogtokh, G. and Ko, Y.T. (2014) Folate-targeted liposome encapsulating chitosan/oligonucleotide polyplexes for tumor targeting. *AAPS PharmSciTech.* **15**, 1087–1092, <https://doi.org/10.1208/s12249-014-0136-5>

- 251 Vahed, S.Z., Salehi, R., Davaran, S. and Sharifi, S. (2017) Liposome-based drug co-delivery systems in cancer cells. *Mater. Sci. Eng.: C* **71**, 1327–1341, <https://doi.org/10.1016/j.msec.2016.11.073>
- 252 Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F. et al. (2018) Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. *J. Control. Release* **288**, 62–83, <https://doi.org/10.1016/j.jconrel.2018.08.043>
- 253 Sun, X., Yan, X., Jacobson, O., Sun, W., Wang, Z., Tong, X. et al. (2017) Improved tumor uptake by optimizing liposome based RES blockade strategy. *Theranostics* **7**, 319, <https://doi.org/10.7150/thno.18078>
- 254 Battogtokh, G., Gotov, O., Kang, J.H., Cho, J., Jeong, T.H., Chimed, G. et al. (2018) Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment. *Nanomedicine* **13**, 325–338, <https://doi.org/10.2217/nnm-2017-0274>
- 255 Paleos, C.M., Tsiourvas, D. and Sideratou, Z. (2016) Triphenylphosphonium decorated liposomes and dendritic polymers: prospective second generation drug delivery systems for targeting mitochondria. *Mol. Pharm.* **13**, 2233–2241, <https://doi.org/10.1021/acs.molpharmaceut.6b00237>
- 256 Pathak, R.K., Kolishetti, N. and Dhar, S. (2015) Targeted nanoparticles in mitochondrial medicine. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **7**, 315–329, <https://doi.org/10.1002/wnan.1305>
- 257 Wang, H., Yin, H., Yan, F., Sun, M., Du, L., Peng, W. et al. (2015) Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance. *Oncotarget* **6**, 2827
- 258 Cabuzu, D., Cirja, A., Puiu, R. and Mihai Grumezescu, A. (2015) Biomedical applications of gold nanoparticles. *Curr. Top. Med. Chem.* **15**, 1605–1613, <https://doi.org/10.2174/1568026615666150414144750>
- 259 Liang, J.-J., Zhou, Y.-Y., Wu, J. and Ding, Y. (2014) Gold nanoparticle-based drug delivery platform for antineoplastic chemotherapy. *Curr. Drug Metab.* **15**, 620–631, <https://doi.org/10.2174/1389200215666140605131427>
- 260 Ahn, S., Lee, I.H., Kang, S., Kim, D., Choi, M., Saw, P.E. et al. (2014) Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy. *Adv. Healthcare Mater.* **3**, 1194–1199, <https://doi.org/10.1002/adhm.201300597>
- 261 Pan, Y., Ding, H., Qin, L., Zhao, X., Cai, J. and Du, B. (2013) Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis. *J. Biomed. Nanotechnol.* **9**, 1746–1756, <https://doi.org/10.1166/jbn.2013.1678>
- 262 Brigger, I., Dubernet, C. and Couvreur, P. (2012) Nanoparticles in cancer therapy and diagnosis. *Adv. Drug. Deliv. Rev.* **64**, 24–36, <https://doi.org/10.1016/j.addr.2012.09.006>
- 263 Gupta, B., Sadaria, D., Warriar, V.U., Kirtonia, A., Kant, R., Awasthi, A. et al. (2020) Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy. *Semin. Cancer Biol.*, <https://doi.org/10.1016/j.semcancer.2020.02.005>
- 264 Reddy, L.H. (2005) Drug delivery to tumours: recent strategies. *J. Pharm. Pharmacol.* **57**, 1231–1242, <https://doi.org/10.1211/jpp.57.10.0001>